[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 21157
6. Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, Faini A, Veltroni M, Husak D, Schumich A, Ratei R, Biondi A, Dworzak MN, I-BFM-ALL-FCM-MRD-Study Group: Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Cytometry B Clin Cytom; 2008 May;74(3):150-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells.
  • BACKGROUND: Immunophenotypic modulation is induced by steroids in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL) patients during remission induction therapy.
  • METHODS: We cultured BCP-ALL blasts from diagnostic bone marrow (BM) samples (n = 20) in the presence of prednisone on stroma layer obtained from BM-derived mesenchymal cells to maintain viability.
  • RESULTS: Leukemia samples that sustained the treatment in vitro with prednisone, showed significative reduction of CD10 and CD34 expression compared with control, and it was comparable with that observed in residual leukemic cells of the same patients in BM at day 15 of treatment.
  • Modulated cells were viable as determined by Annexin V staining and preserved light scattering properties.
  • [MeSH-major] Antigens, CD34 / metabolism. Neprilysin / metabolism. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cells, B-Lymphoid / drug effects. Precursor Cells, B-Lymphoid / immunology. Prednisone / pharmacology
  • [MeSH-minor] Adolescent. Cell Culture Techniques. Child. Child, Preschool. Female. Flow Cytometry. Humans. Immunophenotyping. Infant. Male. Remission Induction

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Clinical Cytometry Society
  • (PMID = 18271020.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD34; EC 3.4.24.11 / Neprilysin; VB0R961HZT / Prednisone
  •  go-up   go-down


7. Satzger I, Völker B, Kofahl-Krause D, Ganser A, Kapp A, Gutzmer R: [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease]. Hautarzt; 2009 Feb;60(2):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravascular lymphoma: two case reports demonstrating the heterogeneity of the disease].
  • [Transliterated title] Intravaskuläre B-Zell-Lymphome: Ein heterogenes Krankheitsbild, dargestellt an 2 Patienten.
  • Intravascular lymphoma (IVL) is a rare subtype of extranodal large-B-cell lymphoma, histologically characterized by accumulation of clonal lymphocytes in small vessels of different organs.
  • The clinical manifestations are highly variable, depending on the involved organs.
  • By means of these two patients, we present the heterogeneity of IVL and discuss current aspects of diagnosis and treatment.
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / drug therapy. Panniculitis / diagnosis. Panniculitis / drug therapy. Vascular Neoplasms / diagnosis. Vascular Neoplasms / drug therapy

  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Aug;18(8):1121-6 [15803190.001]
  • [Cites] Arch Neurol. 2002 Mar;59(3):439-43 [11890850.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] Oncologist. 2006 May;11(5):496-502 [16720850.001]
  • [Cites] J Cutan Med Surg. 2003 Nov-Dec;7(6):460-3 [14605917.001]
  • [Cites] Br J Haematol. 2004 Oct;127(2):173-83 [15461623.001]
  • [Cites] J Neurol. 2000 Aug;247(8):656-8 [11041340.001]
  • [Cites] Blood. 2007 Sep 15;110(6):1713-22 [17540844.001]
  • [Cites] J Am Acad Dermatol. 2002 Nov;47(5 Suppl):S260-2 [12399744.001]
  • [Cites] Am J Surg Pathol. 2006 Sep;30(9):1197-201 [16931967.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):89-91 [11244443.001]
  • [Cites] Leuk Lymphoma. 2006 Feb;47(2):337-41 [16321868.001]
  • [Cites] Hautarzt. 1963 Feb;14:67-70 [13984914.001]
  • [Cites] Ann Hematol. 2004 Sep;83(9):608-10 [15205915.001]
  • [Cites] Br J Dermatol. 1997 Sep;137(3):422-5 [9349342.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2321-2 [11187923.001]
  • [Cites] Bone Marrow Transplant. 2006 Jan;37(2):233-4 [16284609.001]
  • (PMID = 18654750.001).
  • [ISSN] 1432-1173
  • [Journal-full-title] Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
  • [ISO-abbreviation] Hautarzt
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


8. Zhang XX, Xie CH, Xu Y, Deng D, Zhao YH, Zou BW, Zhou L, Li M, Wang J, Liu WP, Huang MJ: Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type. Int J Radiat Oncol Biol Phys; 2009 Jul 1;74(3):747-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage treatment improved survival of patients with relapsed extranodal natural killer/t-cell lymphoma, nasal type.
  • PURPOSE: To evaluate the clinical outcome of salvage treatment for patients with relapsed natural killer (NK)/T-cell lymphoma, nasal type.
  • Among relapsed Stage IIIE and IVE patients who received salvage treatment, RT developed significantly better survival when compared with that of non-RT (1-year OS, 62.5% vs. 0, p = 0.006).
  • CONCLUSIONS: Salvage treatment improved survival in patients with relapsed NK/T-cell lymphoma, nasal type.
  • Salvage RT may play an important role in salvage treatment of relapsed extranodal NK/T-cell lymphoma.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / mortality. Salvage Therapy / mortality

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19304409.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; EPOCH protocol
  •  go-up   go-down


9. Sikder MA, Friedberg JW: Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma. Curr Hematol Malig Rep; 2008 Oct;3(4):187-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beyond rituximab: The future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.
  • The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells.
  • Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies.
  • The goal of these newer agents is to achieve similar or better response rates as seen with rituximab and perhaps demonstrate activity in rituximab-refractory disease.
  • Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Antibodies, Monoclonal, Humanized. Antibodies, Monoclonal, Murine-Derived. Antibodies, Neoplasm / therapeutic use. Clinical Trials as Topic. Humans. Rituximab

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5327-34 [15328168.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4117-26 [15867204.001]
  • [Cites] Blood. 2002 May 15;99(10):3554-61 [11986207.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1216-23 [17470451.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):242-9 [16397048.001]
  • [Cites] J Clin Oncol. 2005 Jul 1;23(19):4390-8 [15994148.001]
  • [Cites] CA Cancer J Clin. 2006 Mar-Apr;56(2):106-30 [16514137.001]
  • [Cites] Clin Cancer Res. 2004 Apr 15;10(8):2868-78 [15102696.001]
  • [Cites] Semin Immunol. 1998 Aug;10(4):287-97 [9695185.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1793-800 [15172969.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] Cancer Res. 2005 Sep 15;65(18):8331-8 [16166310.001]
  • [Cites] Blood. 1984 Nov;64(5):1085-93 [6333257.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1926-30 [12571354.001]
  • [Cites] Oncogene. 2003 Oct 20;22(47):7359-68 [14576843.001]
  • [Cites] J Clin Oncol. 2007 Dec 10;25(35):5616-23 [17984186.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6591-604 [11096108.001]
  • [Cites] N Engl J Med. 1982 Mar 4;306(9):517-22 [6173751.001]
  • [Cites] Arthritis Res Ther. 2006;8(3):R74 [16630358.001]
  • [Cites] Drugs. 2007;67(3):333-50 [17335294.001]
  • [Cites] J Clin Oncol. 2002 Oct 15;20(20):4261-7 [12377971.001]
  • [Cites] Clin Cancer Res. 2004 Aug 15;10(16):5297-8 [15328164.001]
  • [Cites] Blood. 2008 Feb 1;111(3):1094-100 [18003886.001]
  • [Cites] Hematology Am Soc Hematol Educ Program. 2005;:329-34 [16304399.001]
  • [Cites] J Clin Oncol. 2003 Aug 15;21(16):3051-9 [12837807.001]
  • [Cites] Nature. 1975 Aug 7;256(5517):495-7 [1172191.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3135-43 [10963642.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] Lancet Oncol. 2006 May;7(5):379-91 [16648042.001]
  • [Cites] J Immunol. 2000 Apr 15;164(8):4178-84 [10754313.001]
  • [Cites] Clin Cancer Res. 2003 Sep 1;9(10 Pt 2):3995S-4002S [14506199.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5044-51 [15955901.001]
  • (PMID = 20425465.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / PRO131921 monoclonal antibody; 0 / dacetuzumab; 0 / epratuzumab; 0 / ocrelizumab; 0 / veltuzumab; 357613-77-5 / galiximab; 3A189DH42V / alemtuzumab; 4F4X42SYQ6 / Rituximab; M95KG522R0 / ofatumumab
  • [Number-of-references] 37
  •  go-up   go-down


10. Hara S, Yokote T, Akioka T, Oka S, Yamano T, Tsuji M, Hanafusa T: [Successful treatment of refractory mantle cell lymphoma with irinotecan]. Rinsho Ketsueki; 2005 May;46(5):358-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment of refractory mantle cell lymphoma with irinotecan].
  • An inguinal lymph node biopsy showed mantle cell lymphoma (MCL).
  • [MeSH-major] Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Lymphoma, Mantle-Cell / drug therapy

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16444969.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  • [Number-of-references] 16
  •  go-up   go-down


11. Mergan F, Jaubert F, Sauvat F, Hartmann O, Lortat-Jacob S, Révillon Y, Nihoul-Fékété C, Sarnacki S: Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis. J Pediatr Surg; 2005 Oct;40(10):1581-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inflammatory myofibroblastic tumor in children: clinical review with anaplastic lymphoma kinase, Epstein-Barr virus, and human herpesvirus 8 detection analysis.
  • BACKGROUND/PURPOSE: Inflammatory myofibroblastic tumor (IMT) is considered as an intermediate neoplasm that may present malignant features.
  • Differential diagnosis with other tumor processes is sometimes difficult.
  • Similar anaplastic lymphoma kinase (ALK) gene abnormalities as in anaplastic large cell lymphoma have been reported.
  • This article aims to evaluate ALK, EBV, and HHV-8 expression in children with IMT and to correlate our findings with clinical features.
  • All patients are now disease-free with a mean follow-up of 4.2 years.
  • [MeSH-major] Granuloma, Plasma Cell / enzymology. Granuloma, Plasma Cell / virology. Herpesvirus 4, Human / isolation & purification. Herpesvirus 8, Human / isolation & purification. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases / analysis

  • Genetic Alliance. consumer health - Inflammatory myofibroblastic tumor.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16226988.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


12. Rasheed W, Bishton M, Johnstone RW, Prince HM: Histone deacetylase inhibitors in lymphoma and solid malignancies. Expert Rev Anticancer Ther; 2008 Mar;8(3):413-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Histone deacetylase inhibitors in lymphoma and solid malignancies.
  • Based on these preclinical findings, in recent years HDACi have undergone a rapid phase of clinical development with many HDACi entering Phase I-III clinical trials, both as single agents and in combination with other therapies.
  • Favorable clinical responses have been demonstrated in cutaneous T-cell lymphoma with emerging evidence of clinical activity in other types of lymphoma and, to date, a good toxicity profile.
  • In this review we discuss the recent advances in the clinical development of HDACi and their current therapeutic role in lymphoma and solid malignancies.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Histone Deacetylase Inhibitors. Lymphoma / drug therapy. Neoplasms / drug therapy
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Benzamides / therapeutic use. Depsipeptides / therapeutic use. Drug Resistance, Neoplasm. Humans. Hydroxamic Acids / therapeutic use. Indoles. Neoplasm Recurrence, Local. Pyridines / therapeutic use. Pyrimidines / therapeutic use

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. Vorinostat .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18366289.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Depsipeptides; 0 / Histone Deacetylase Inhibitors; 0 / Hydroxamic Acids; 0 / Indoles; 0 / Pyridines; 0 / Pyrimidines; 1ZNY4FKK9H / entinostat; 58IFB293JI / vorinostat; 9647FM7Y3Z / panobinostat; A6GWB8T96J / mocetinostat; CX3T89XQBK / romidepsin
  • [Number-of-references] 158
  •  go-up   go-down


13. Kiss TL, Mollee P, Lazarus HM, Lipton JH: Stem cell transplantation for mantle cell lymphoma: if, when and how? Bone Marrow Transplant; 2005 Oct;36(8):655-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stem cell transplantation for mantle cell lymphoma: if, when and how?
  • Although the prognosis for mantle cell lymphoma (MCL) patients has improved in recent years, the outlook for those with advanced or recurrent disease remains poor.
  • Trials designed to look at newly diagnosed patients with MCL examining the outcomes after planned autologous and allogeneic transplant as part of the initial management are needed to confirm the role of these various modalities in the overall therapy of this poor-outcome lymphoma.
  • [MeSH-major] Lymphoma, Mantle-Cell / therapy. Stem Cell Transplantation / methods
  • [MeSH-minor] Clinical Trials as Topic. Humans. Multicenter Studies as Topic

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007106.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 48
  •  go-up   go-down


1
Advertisement
4. McCann S, Schwenkglenks M, Bacon P, Einsele H, D'Addio A, Maertens J, Niederwieser D, Rabitsch W, Roosaar A, Ruutu T, Schouten H, Stone R, Vorkurka S, Quinn B, Blijlevens N, EBMT Mucositis Advisory Group: The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant; 2009 Jan;43(2):141-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT.
  • The Prospective Oral Mucositis Audit was an observational study in 197 patients with multiple myeloma (MM) or non-Hodgkin's lymphoma (NHL) undergoing, respectively, high-dose melphalan or BEAM chemotherapy and autologous SCT at 25 European centres.
  • We evaluated the relationship between severe oral mucositis (SOM; WHO Oral Toxicity Scale grade 3-4) and local and systemic clinical sequelae and medical resource use.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Lymphoma, Non-Hodgkin / therapy. Multiple Myeloma / therapy. Stem Cell Transplantation / adverse effects. Stomatitis / etiology. Transplantation Conditioning / adverse effects

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18776926.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Analgesics, Opioid; 0 / Anti-Bacterial Agents; 04079A1RDZ / Cytarabine; 6PLQ3CP4P3 / Etoposide; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; BEAM regimen
  •  go-up   go-down


15. Benabid L, Desablens B, Brevet M, Malthieu D, Milazzo S, Turut P: [Orbital non-Hodgkin's lymphoma: a retrospective study of 22 patients]. J Fr Ophtalmol; 2005 Dec;28(10):1058-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Orbital non-Hodgkin's lymphoma: a retrospective study of 22 patients].
  • [Transliterated title] Les lymphomes malins non hodgkiniens conjonctivo-orbitaires.
  • INTRODUCTION: Although the number of non-Hodgkin's lymphoma (NHL) cases continues to grow throughout the world, orbital NHL is still a rare tumor that is difficult to diagnose.
  • MATERIAL AND METHODS: [corrected] We conducted a retrospective study of conjunctive-orbital lymphomas diagnosed in the Amiens Ophthalmology Department between 1982 and 2002.
  • The pathological reports of 22 cases were investigated, notably the mode of onset, the clinical and radiological description, the diagnostic mode, pathological results, and the type of treatment provided for these tumors.
  • RESULTS: Every NHL was type B.
  • This may explain delayed diagnosis.
  • The first differential diagnosis is inflammatory pseudotumor.
  • Only a good biopsy can confirm the diagnosis of NHL.
  • CONCLUSION: New immunohistochemistry and genetic diagnostic methods make it increasingly possible to screen for NHL, even if the clinical history can be misleading.
  • Moreover, treatments that are more and more precisely targeted to the immunohistochemical type of NHL seem to be giving very promising results.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, B-Cell / therapy. Orbital Neoplasms / diagnosis. Orbital Neoplasms / therapy

  • Genetic Alliance. consumer health - Orbital lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16395197.001).
  • [ISSN] 1773-0597
  • [Journal-full-title] Journal français d'ophtalmologie
  • [ISO-abbreviation] J Fr Ophtalmol
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


16. Robak E, Biernat W, Krykowski E, Jeziorski A, Robak T: Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab. Leuk Lymphoma; 2005 Jun;46(6):909-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Merkel cell carcinoma in a patient with B-cell chronic lymphocytic leukemia treated with cladribine and rituximab.
  • Merkel cell carcinoma (MCC) is an uncommon, neuroendocrine skin tumor with an aggressive clinical course.
  • The etiology of the disease is unknown, although sun exposure and immunosuppression may play a role in its development.
  • Coexistence of MCC with chronic lymphocytic leukemia (CLL) is extremely rare and to our knowledge it has been previously described in only 8 patients.
  • Histopathological and immunohistochemical evaluation of the cervical lymph node specimens showed monotonous and diffuse infiltrate of small CD5+, CD20+, CD23+ lymphocytes and no MCC cells were present.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Merkel Cell / complications. Carcinoma, Merkel Cell / drug therapy. Cladribine / therapeutic use. Leukemia, B-Cell / complications. Leukemia, B-Cell / drug therapy. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy. Skin Neoplasms / complications. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. CLADRIBINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019537.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Immunosuppressive Agents; 47M74X9YT5 / Cladribine; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


17. Mohsin N, Budruddin M, Kamble P, Khalil M, Pakkyarra A, Jha A, Mohammed E, Ahmed H, Ahmed J, Thomas S, Campistol JM, Daar A: Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus. Transplant Proc; 2007 May;39(4):1267-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete regression of cutaneous B-cell lymphoma in a renal transplant patient after conversion from cyclosporin to sirolimus.
  • Posttransplant lymphoproliferative disease remains a serious morbidity.
  • Herein we have reported a case of complete regression of a biopsy-proven B-cell lymphoma that occurred in the posttransplant period.
  • A 48-year-old man received a living donor renal transplant for end-stage renal disease due to undetermined etiology.
  • A biopsy of the nodules revealed B-cell lymphoma.
  • The patient remains well without clinical relapses at 19 months after conversion.
  • [MeSH-major] Cyclosporine / adverse effects. Kidney Transplantation / adverse effects. Lymphoma, B-Cell / immunology. Neoplasm Regression, Spontaneous. Sirolimus / therapeutic use

  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • Hazardous Substances Data Bank. CYCLOSPORIN A .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17524950.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 83HN0GTJ6D / Cyclosporine; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


18. Beckhove P, Warta R, Lemke B, Stoycheva D, Momburg F, Schnölzer M, Warnken U, Schmitz-Winnenthal H, Ahmadi R, Dyckhoff G, Bucur M, Jünger S, Schueler T, Lennerz V, Woelfel T, Unterberg A, Herold-Mende C: Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation. J Clin Invest; 2010 Jun;120(6):2230-42
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid T cell-based identification of human tumor tissue antigens by automated two-dimensional protein fractionation.
  • This study describes what we believe to be a new method of comprehensively identifying candidate tissue antigens that spontaneously cause T cell responses in disease situations.
  • We used the newly developed automated, two-dimensional chromatography system PF2D to fractionate the proteome of human tumor tissues and tested protein fractions for recognition by preexisting tumor-specific CD4+ Th cells and CTLs.
  • Applying this method using mice transgenic for a TCR that recognizes an OVA peptide presented by MHC class I, we demonstrated efficient separation, processing, and cross-presentation to CD8+ T cells by DCs of OVA expressed by the OVA-transfected mouse lymphoma RMA-OVA.
  • Applying this method to human tumor tissues, we identified MUC1 and EGFR as tumor-associated antigens selectively recognized by T cells in patients with head and neck cancer.
  • Finally, in an exemplary patient with a malignant brain tumor, we detected CD4+ and CD8+ T cell responses against two novel antigens, transthyretin and calgranulin B/S100A9, which were expressed in tumor and endothelial cells.
  • This fast and inexpensive method therefore appears suitable for identifying candidate T cell antigens in various disease situations, such as autoimmune and malignant diseases, without being restricted to expression by a certain cell type or HLA allele.
  • [MeSH-major] Antigens, Neoplasm / chemistry. Antigens, Neoplasm / immunology. Peptides / chemistry. Peptides / immunology. T-Lymphocytes / immunology

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):35-42 [15951525.001]
  • [Cites] Cancer Biol Ther. 2005 Sep;4(9):943-8 [16082191.001]
  • [Cites] Cancer Res. 2006 Jun 15;66(12):5997-6001 [16778169.001]
  • [Cites] Cancer Res. 2006 Aug 15;66(16):8258-65 [16912206.001]
  • [Cites] J Ind Microbiol Biotechnol. 2006 Nov;33(11):914-20 [16964509.001]
  • [Cites] Anal Biochem. 2006 Dec 1;359(1):84-93 [17034751.001]
  • [Cites] Arch Pharm Res. 2007 Jan;30(1):75-81 [17328245.001]
  • [Cites] FEBS J. 2007 Apr;274(7):1637-50 [17381508.001]
  • [Cites] J Neurosci Methods. 2007 Apr 15;161(2):250-8 [17207861.001]
  • [Cites] J Proteome Res. 2007 Jun;6(6):2168-75 [17488104.001]
  • [Cites] Tissue Antigens. 2007 Oct;70(4):319-23 [17767554.001]
  • [Cites] Cancer. 2008 Mar 15;112(6):1313-24 [18257091.001]
  • [Cites] Proteomics. 2008 Jun;8(11):2168-77 [18528841.001]
  • [Cites] Anal Chim Acta. 2008 Oct 3;627(1):71-81 [18790129.001]
  • [Cites] J Immunother. 2009 Jan;32(1):92-9 [19307998.001]
  • [Cites] J Neurooncol. 2009 Aug;94(1):31-9 [19219580.001]
  • [Cites] Clin Cancer Res. 2009 Sep 1;15(17):5323-37 [19723653.001]
  • [Cites] J Clin Invest. 2009 Nov;119(11):3311-21 [19809157.001]
  • [Cites] J Immunother. 2010 Jan;33(1):83-91 [19952953.001]
  • [Cites] Nat Med. 2001 Apr;7(4):452-8 [11283672.001]
  • [Cites] Immunogenetics. 1999 Nov;50(3-4):213-9 [10602881.001]
  • [Cites] Lab Invest. 1999 Dec;79(12):1573-82 [10616207.001]
  • [Cites] Eur J Immunol. 2000 Aug;30(8):2216-25 [10940913.001]
  • [Cites] J Biol Chem. 2001 Jan 12;276(2):1107-13 [11036082.001]
  • [Cites] DNA Cell Biol. 2002 Jan;21(1):11-9 [11879576.001]
  • [Cites] Cancer Res. 2002 Oct 15;62(20):5818-27 [12384544.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6823-6 [12460893.001]
  • [Cites] Int Immunol. 2003 Jun;15(6):751-63 [12750359.001]
  • [Cites] Anticancer Res. 2003 May-Jun;23(3A):2043-51 [12894577.001]
  • [Cites] C R Biol. 2003 Oct-Nov;326(10-11):1067-72 [14744114.001]
  • [Cites] J Biol Chem. 1971 Jan 10;246(1):44-9 [5541771.001]
  • [Cites] Biochemistry. 1978 Dec 26;17(26):5729-33 [728432.001]
  • [Cites] Int J Cancer. 1989 Jun 15;43(6):1072-6 [2471698.001]
  • [Cites] Science. 1994 Apr 29;264(5159):716-9 [7513441.001]
  • [Cites] Eur J Immunol. 1994 Sep;24(9):2068-72 [8088327.001]
  • [Cites] Mol Immunol. 1994 Dec;31(18):1423-30 [7823968.001]
  • [Cites] J Immunol. 1995 Nov 15;155(10):4676-84 [7594467.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Dec 5;92(25):11810-3 [8524854.001]
  • [Cites] APMIS. 1996 Feb;104(2):115-25 [8619913.001]
  • [Cites] Annu Rev Immunol. 1996;14:333-67 [8717518.001]
  • [Cites] J Immunol. 1998 Feb 1;160(3):1427-35 [9570563.001]
  • [Cites] Cancer Res. 2004 Dec 15;64(24):9018-26 [15604267.001]
  • [Cites] Cancer Immunol Immunother. 2005 Mar;54(3):187-207 [15309328.001]
  • [Cites] Blood. 2005 Mar 1;105(5):2132-4 [15561890.001]
  • [Cites] Histopathology. 2005 Mar;46(3):256-69 [15720411.001]
  • [Cites] Proteomics. 2005 Jul;5(10):2641-7 [15912557.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Nov 1;102(44):16013-8 [16247014.001]
  • [Cites] Mol Cell Proteomics. 2006 Jan;5(1):26-34 [16188874.001]
  • (PMID = 20458140.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens; 0 / Antigens, Neoplasm; 0 / HLA Antigens; 0 / Peptides; 0 / Proteins
  • [Other-IDs] NLM/ PMC2877924
  •  go-up   go-down


19. Janssen U, Amann K, Reumel J, Boehm J, Verbeek W: Low-grade T-cell lymphoma of the kidney and Waldenström's macroglobulinemia in a patient presenting with renal failure. Clin Nephrol; 2006 Jun;65(6):441-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Low-grade T-cell lymphoma of the kidney and Waldenström's macroglobulinemia in a patient presenting with renal failure.
  • Renal failure is rarely the presenting manifestation of non-Hodgkin's lymphoma.
  • We describe the unusual case of a patient who presented with uremia due to lymphomatous infiltration of the kidney by a low-grade T-cell lymphoma.
  • The diagnosis of lymphoma was made by renal biopsy.
  • However, simultaneously, a lymphoplasmacytic lymphoma was found on bone marrow biopsy associated with IgM paraproteinemia.
  • To our knowledge, this is the first report of a renal T-cell lymphoma associated with Waldenström's macroglobulinemia.
  • [MeSH-major] Kidney Diseases / diagnosis. Lymphoma, T-Cell / diagnosis. Renal Insufficiency / complications. Waldenstrom Macroglobulinemia / complications. Waldenstrom Macroglobulinemia / diagnosis

  • MedlinePlus Health Information. consumer health - Kidney Diseases.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16792141.001).
  • [ISSN] 0301-0430
  • [Journal-full-title] Clinical nephrology
  • [ISO-abbreviation] Clin. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Serum Albumin; 0 / gamma-Globulins
  •  go-up   go-down


20. He X, Tian C, Yang D, Xie X, Liu H: [Analysis on clinicopathologic characteristics of 216 primary extranodular non-Hodgkin's lymphoma in head and neck]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2009 Oct;23(19):878-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis on clinicopathologic characteristics of 216 primary extranodular non-Hodgkin's lymphoma in head and neck].
  • OBJECTIVE: To study the clinicopathologic characteristic of the primary extranodular non Hodgkin's lymphoma in head and neck.
  • METHOD: Clinical manifestation and the characteristic of clinicopathology of 216 extranodular non-Hodgkin's lymphoma patients in head and neck were analyzed retrospectively.
  • The most common histologic subtype was NK/T cell lymphoma, which accounted for 49.5% (107 cases) of cases, secondly was diffuse large B cell lymphoma (DLBCL, 58 cases, 26.7%).
  • The most common histologic subtype in different stach groups respectively is: NK/T cell lymphoma in nasal cavity (74 cases,77.9%), DLBCL in paranasal sinus (6 cases, 50.0%), DLBCL in tonsil (27 cases, 57.4%), NK/T cell lymphoma in nasopharynx (17 cases, 44.7%), and DLBCL in lingual root (5 cases, 45.4%).
  • CONCLUSION: We conclude that primary extranodular non-Hodgkin's lymphoma is common in head and neck patients.
  • There is characteristic in age, primary involved site and histologic subtype, which is helpful to understand these characteristic for pathologic diagnosis.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20120872.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


21. Higashiyama A, Hashino S, Onozawa M, Takahata M, Okada K, Kahata K, Taniguchi N, Nasuhara Y, Kubota K, Fujimoto N, Matsuno Y, Nishimura M, Asaka M: [Intravascular large B-cell lymphoma with massive pulmonary lesions]. Rinsho Ketsueki; 2010 May;51(5):353-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Intravascular large B-cell lymphoma with massive pulmonary lesions].
  • The TBLB specimen was diagnosed as intravascular large B-cell lymphoma (IVLBCL).
  • In cases showing clinical findings such as hypoxia despite mild pulmonary radiographic changes, a definitive diagnosis should be made using methods such as TBLB with consideration given to the possibility of IVLBCL.
  • [MeSH-major] Lung Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Vascular Neoplasms / diagnosis. Vascular Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20534958.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; VAP-cyclo protocol
  • [Number-of-references] 5
  •  go-up   go-down


22. Wang Z: [Nasal extranodal NK/T cell lymphoma: terminologic evaluation and diagnostic problems]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Sep;24(17):791-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Nasal extranodal NK/T cell lymphoma: terminologic evaluation and diagnostic problems].
  • OBJECTIVE: To review on the evolution in the understanding of midline destructive lesions of the sinonasal tract in different period, and to describe the clinical features and diagnostic problems on the nasal extranodal NK/T cell lymphoma (NENKTCL).
  • METHOD: To retrospectively study the nasal CT scannings and the results of serum ANCA of 10 patients with typical clinical characteristics.
  • Epistaxis and facial swelling were in the clinical spectrum.
  • CONCLUSION: Outdated terminology referring to midline lesions includes a variety of diseases, and NENKTCL is an independent disease focusing on destructive lesions of face and nose.
  • [MeSH-major] Lymphoma, Extranodal NK-T-Cell / diagnosis. Nose Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21090103.001).
  • [ISSN] 1001-1781
  • [Journal-full-title] Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology, head, and neck surgery
  • [ISO-abbreviation] Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


23. Kawaguchi T, Nosaka K: [Clinical values of biomarkers in hematopoietic malignancies]. Gan To Kagaku Ryoho; 2009 Jan;36(1):26-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical values of biomarkers in hematopoietic malignancies].
  • Hematopoietic malignancies include leukemia, lymphoma and multiple myeloma.
  • These diseases are primarily diagnosed on the basis of morphological features of affected cells, which appear in peripheral blood, bone marrow and lymphoid organs.
  • By taking advantage of the repetitive accessibility of the neoplastic cells within the peripheral blood / and/or bone marrow aspirates, morphological tests are conducted not only for diagnosis but also for evaluation of clinical outcomes and prognosis, suggesting that the morphological features are considered as a clinical biomarker in hematopoietic malignancies.
  • However, remarkable progress in molecular targeted therapy and allogeneic hematopoietic stem cell transplantation has improved the long-term prognosis of patients with hematopoietic malignancies, and some patients are curable.
  • Under such modern strategies for therapy, monitoring of minimal residual disease(MRD), which is morphologically undetectable, is required to guide proper management of the disease by evaluation of an optimal response to therapy and early detection of disease relapse.
  • BCR-ABL in chronic myeloid leukemia)characteristic of hematopoietic malignant cells are analyzed as clinically useful biomarkers to monitor MRD by two highly sensitive methods, multiparameter flow cytometry and real-time quantitative PCR, respectively.
  • On the other hand, serum markers reflecting the size of the tumor mass are clinically available to monitor the disease progression in mass-forming hematopoietic malignancies: e. g., soluble IL-2 receptor for lymphoma and M-protein or free light chain for multiple myeloma.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19151562.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers
  •  go-up   go-down


24. Mikhaeel NG: Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now? Leuk Lymphoma; 2009 Dec;50(12):1931-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interim fluorodeoxyglucose positron emission tomography for early response assessment in diffuse large B cell lymphoma: where are we now?
  • Fluorodeoxyglucose (FDG)-positron emission tomography (PET) has been established in response assessment after treatment of diffuse large B cell lymphoma (DLBCL) and has been incorporated in the International Workshop Criteria (IWC).
  • Early response assessment is increasingly being used in trials and clinical practice with the hope that it has a greater power to discriminate between good and poor prognosis patients at an earlier point in time.
  • However, the prognosis of responders/non-responders has been different in various studies, with few recent studies casting some doubt on the value of interim PET.
  • There is a need for a consensus on a uniform methodology for the use of interim PET both in clinical trials and routine clinical practice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Fluorodeoxyglucose F18. Lymphoma, Large B-Cell, Diffuse / drug therapy. Positron-Emission Tomography / methods

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001245.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  • [Number-of-references] 31
  •  go-up   go-down


25. Bor O, Cagri Dinleyici E, Kiraz N, Dundar E, Akdeniz Akgun N: Successful treatment of tongue aspergillosis caused by Aspergillus flavus with liposomal amphotericin B in a child with acute lymphoblastic leukemia. Med Mycol; 2006 Dec;44(8):767-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An increase in the systemic dose (7 mg/kg/day) and local intraoral delivery of liposomal amphotericin B was successful in treating the patient and resulted in improved clinical and laboratory findings.
  • [MeSH-major] Amphotericin B / therapeutic use. Antifungal Agents / therapeutic use. Aspergillosis / drug therapy. Aspergillus flavus / isolation & purification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tongue Diseases / drug therapy


36. Parveen Z, Thompson K: Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas. Arch Pathol Lab Med; 2009 Feb;133(2):303-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T-cell lymphoma: redefinition of diagnostic criteria in the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas.
  • Subcutaneous panniculitis-like T-cell lymphoma is a primary T-cell lymphoma that preferentially involves the subcutaneous tissue.
  • Although subcutaneous panniculitis-like T-cell lymphoma has been recognized as a distinctive entity in the category of peripheral T-cell lymphoma in the World Health Organization classification, its diagnostic criteria has been redefined by the recent World Health Organization-European Organization for Research and Treatment of Cancer classification for primary cutaneous lymphomas.
  • Subcutaneous panniculitis-like T-cell lymphoma is now restricted to primary cutaneous T-cell lymphoma expressing alphabeta T-cell receptor phenotype.
  • These lymphomas are usually CD3(+), CD4(-), CD8(+), and CD56(-), and usually have an indolent clinical course.
  • The clinicopathologic features, differential diagnosis, immunophenotypic characteristics, and molecular features of subcutaneous panniculitis-like T-cell lymphoma are presented in light of the recent World Health Organization-European Organization for Research and Treatment of Cancer classification.
  • [MeSH-major] Lymphoma, T-Cell, Cutaneous / diagnosis. Skin Neoplasms / diagnosis. World Health Organization


37. Woods NB, Bottero V, Schmidt M, von Kalle C, Verma IM: Gene therapy: therapeutic gene causing lymphoma. Nature; 2006 Apr 27;440(7088):1123
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene therapy: therapeutic gene causing lymphoma.
  • The development of T-cell leukaemia following the otherwise successful treatment of three patients with X-linked severe combined immune deficiency (X-SCID) in gene-therapy trials using haematopoietic stem cells has led to a re-evaluation of this approach.
  • Using a mouse model for gene therapy of X-SCID, we find that the corrective therapeutic gene IL2RG itself can act as a contributor to the genesis of T-cell lymphomas, with one-third of animals being affected.
  • [MeSH-major] Disease Models, Animal. Genetic Therapy / adverse effects. Lymphoma, T-Cell / genetics. Oncogenes / genetics. Receptors, Interleukin-2 / genetics. Severe Combined Immunodeficiency / genetics. Severe Combined Immunodeficiency / therapy
  • [MeSH-minor] Animals. Cell Transformation, Neoplastic / genetics. Clinical Trials as Topic / adverse effects. Clinical Trials as Topic / methods. Dogs. Hematopoietic Stem Cell Transplantation. Humans. Mice. Mice, SCID. Time Factors


38. Piriou E, van Dort K, Nanlohy NM, van Oers MH, Miedema F, van Baarle D: Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood; 2005 Nov 1;106(9):3166-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of EBNA1-specific memory CD4+ and CD8+ T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma.
  • We previously observed a loss of Epstein-Barr virus (EBV)-specific CD8+ T cells in subjects progressing to EBV-related non-Hodgkin lymphoma (NHL), correlating with loss of CD4+ T cells.
  • The aim of the present study was to determine the role of EBV-specific CD4+ T cells in the development of NHL during chronic HIV infection.
  • To this end, CD4+ and CD8+ memory T cells, capable of both proliferation and subsequent interferon gamma (IFNgamma) production, directed against a latent (Epstein-Barr virus nuclear antigen 1 [EBNA1]) and a lytic (BamH fragment Z left frame 1 [BZLF1]) EBV antigen were studied longitudinally in 9 progressors to NHL, 4 progressors to non-EBV-related AIDS, and 4 slow progressors to AIDS.
  • In all 3 groups we observed a decline of EBV-specific memory CD4+ and CD8+ T-cell responses during HIV infection.
  • However, whereas latent antigen EBNA1-specific CD4+ T cells were lost well before diagnosis in all subjects who developed an AIDS-related NHL (and EBNA1-specific CD8+ T cells were significantly lower compared with the other groups), these cells were better preserved in progressors to non-EBV-related disease and slow progressors.
  • Loss of EBNA1-specific T-cell immunity thus might be important for progression to NHL.
  • Interestingly, BZLF1-specific T cells were not lost in all progressors to NHL, suggesting a different function of these cells in the surveillance of EBV-infected B cells.
  • [MeSH-major] CD4-Positive T-Lymphocytes / immunology. CD8-Positive T-Lymphocytes / immunology. Epstein-Barr Virus Nuclear Antigens / immunology. Immunologic Memory / immunology. Lymphoma, AIDS-Related / immunology. Lymphoma, Non-Hodgkin / complications. Lymphoma, Non-Hodgkin / immunology
  • [MeSH-minor] Acquired Immunodeficiency Syndrome / complications. Acquired Immunodeficiency Syndrome / immunology. Acquired Immunodeficiency Syndrome / virology. Adult. Cell Proliferation. Disease Progression. HIV-1 / immunology. HIV-1 / physiology. Humans. Kinetics. Middle Aged


39. Bishton MJ, Haynes AP: Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma. Br J Haematol; 2007 Jan;136(1):111-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination chemotherapy followed by autologous stem cell transplant for enteropathy-associated T cell lymphoma.
  • Enteropathy-associated T cell lymphoma (EATL) is a rare entity associated with coeliac disease, with a poor prognosis due to perforation and gastro-intestinal bleeding during treatment, and a high relapse risk.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Celiac Disease / complications. Lymphoma, T-Cell, Peripheral / complications. Lymphoma, T-Cell, Peripheral / therapy. Peripheral Blood Stem Cell Transplantation

  • Genetic Alliance. consumer health - Enteropathy-Associated T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. MELPHALAN .
  • Hazardous Substances Data Bank. Carmustine .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. PODOFILOX .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2007 Apr;137(2):170; author reply 171 [17391498.001]
  • (PMID = 17116129.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; L36H50F353 / Podophyllotoxin; Q41OR9510P / Melphalan; U68WG3173Y / Carmustine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate; BEAM protocol; IEV protocol
  •  go-up   go-down


40. Gutiérrez A, Caballero MD, Pérez-Manga G, Rodriguez J: Hematopoietic SCT for peripheral T-cell lymphoma. Bone Marrow Transplant; 2008 Dec;42(12):773-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hematopoietic SCT for peripheral T-cell lymphoma.
  • Results of conventional chemotherapy for high-risk peripheral T-cell lymphoma (PTCL) are poor compared with those for their aggressive B-cell counterparts.
  • With respect to autologous SCT (ASCT), conclusions from retrospective studies are that ASCT in the salvage setting is as useful in PTCL as in aggressive B-cell lymphomas and also that consolidation in first complete response of high-risk patients has very good results when compared with conventional chemotherapy (with long-term PFS higher than 50%).
  • From first frontline prospective clinical trials, it appears that ASCT is feasible and has a low TRM (<5%); consolidation in first complete response is associated with a very good outcome; around 25% of patients do not undergo ASCT due mainly to disease progression; new approaches aimed at increasing the number of chemosensitive patients should be found.
  • For this reason, Allo-SCT procedures are the object of ongoing clinical trials.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / therapy. Salvage Therapy
  • [MeSH-minor] Drug Resistance, Neoplasm. Humans. Remission Induction / methods. Survival Analysis. Transplantation Conditioning. Transplantation, Autologous. Transplantation, Homologous

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18936735.001).
  • [ISSN] 1476-5365
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


41. Jin L, Tabe Y, Kojima K, Zhou Y, Pittaluga S, Konopleva M, Miida T, Raffeld M: MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma. Cancer Lett; 2010 Dec 28;299(2):161-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MDM2 antagonist Nutlin-3 enhances bortezomib-mediated mitochondrial apoptosis in TP53-mutated mantle cell lymphoma.
  • This study demonstrated a pronounced synergistic growth-inhibitory effect of an MDM2 inhibitor Nutlin-3 and a proteasome inhibitor bortezomib in mantle cell lymphoma (MCL) cells regardless of TP53 mutant status and innate bortezomib sensitivity.
  • In the mutant TP53 MCL cells which are intrinsically resistant to bortezomib, the combination of Nutlin-3/bortezomib synergistically induced cytotoxicity through the mitochondrial apoptotic pathway mediated by transcription-independent upregulation of NOXA, sequestration of MCL-1, activation of BAX, BAK, caspase-9 and -3.
  • In the bortezomib sensitive wild-type TP53 MCL cells, the Nutlin-3/bortezomib combination caused G0/G1 cell cycle arrest followed by the increase in apoptosis induction.
  • [MeSH-minor] Antineoplastic Agents / pharmacology. Blotting, Western. Bortezomib. Caspase 3 / metabolism. Caspase 9 / metabolism. Cell Cycle / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Dose-Response Relationship, Drug. Drug Synergism. Humans. Lymphoma, Mantle-Cell / genetics. Lymphoma, Mantle-Cell / metabolism. Lymphoma, Mantle-Cell / pathology. Mitochondria / drug effects. Mitochondria / metabolism. Mutation. Myeloid Cell Leukemia Sequence 1 Protein. Proto-Oncogene Proteins c-bcl-2 / genetics. Proto-Oncogene Proteins c-bcl-2 / metabolism. Proto-Oncogene Proteins c-mdm2 / antagonists & inhibitors. Proto-Oncogene Proteins c-mdm2 / metabolism. Reverse Transcriptase Polymerase Chain Reaction. Tumor Suppressor Protein p53 / genetics. bcl-2 Homologous Antagonist-Killer Protein / metabolism. bcl-2-Associated X Protein / metabolism

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Ireland Ltd. All rights reserved.
  • (PMID = 20850924.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Imidazoles; 0 / Myeloid Cell Leukemia Sequence 1 Protein; 0 / PMAIP1 protein, human; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Pyrazines; 0 / Tumor Suppressor Protein p53; 0 / bcl-2 Homologous Antagonist-Killer Protein; 0 / bcl-2-Associated X Protein; 0 / nutlin 3; 69G8BD63PP / Bortezomib; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspase 9; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


42. Kwong YL: Predicting the outcome in non-Hodgkin lymphoma with molecular markers. Br J Haematol; 2007 May;137(4):273-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Predicting the outcome in non-Hodgkin lymphoma with molecular markers.
  • The World Health Organization classification divides non-Hodgkin lymphomas into B-cell, T-cell and natural killer-cell lymphomas.
  • Clinical prognostic indices rely only on patient factors and staging.
  • Molecular prognostic markers reflect the intrinsic lymphoma biology, measure tumour load and may provide novel therapeutic targets.
  • Lymphomagenesis involves mutations, deletions or dysregulations of genes critical in the control of cell cycle and apoptosis, which are in turn prognostically important.
  • Genome-wide gene expression profiling, either by allowing lymphomas to be classified according to different stages of lymphoid maturation, or by defining specific gene expression signatures, is also of prognostic significance.
  • In lymphomas where viral infections of the neoplastic cells occur, quantification of viral copies is a surrogate marker for tumour load and hence prognosis.
  • [MeSH-major] Lymphoma, Non-Hodgkin / genetics

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17408399.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Genetic Markers
  • [Number-of-references] 108
  •  go-up   go-down


43. Johnston PB, Bondly C, Micallef IN: Ibritumomab tiuxetan for non-Hodgkin's lymphoma. Expert Rev Anticancer Ther; 2006 Jun;6(6):861-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ibritumomab tiuxetan for non-Hodgkin's lymphoma.
  • Targeted radiation therapy, or radioimmunotherapy, has been an important recent advancement in the treatment of patients with B-cell non-Hodgkin's lymphoma (NHL).
  • 90Y ibritumomab tiuxetan has been demonstrated to be efficacious in the treatment of B-cell NHL.
  • Currently, there are many ongoing trials of ibritumomab tiuxetan with different dose schedules and intensities, in combination with chemotherapy and with stem cell transplantation, in an attempt to improve response rate and duration and to study its effectiveness in other B-cell lymphomas, including diffuse large B-cell lymphoma and mantle cell lymphoma.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Antigens, CD20. Clinical Trials as Topic. Drug Approval. Humans. Patient Selection. Yttrium Radioisotopes

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16761929.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD20; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  • [Number-of-references] 39
  •  go-up   go-down


44. Cobo F, García C, Talavera P, Ruiz-Cabello F, Bravo J, Concha A: Diffuse large B-cell lymphoma in a renal allograft associated with Epstein-Barr virus in the recipient: a case report and a review of lymphomas presenting in a transplanted kidney. Clin Transplant; 2008 Jul-Aug;22(4):512-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma in a renal allograft associated with Epstein-Barr virus in the recipient: a case report and a review of lymphomas presenting in a transplanted kidney.
  • We also report a rare case of diffuse large B-cell lymphoma originated from the lymphocytes of the recipient with exclusive localization in the kidney allograft.
  • We found only 16 cases of lymphoma presenting in the kidney allograft without systemic affectation.
  • The most frequent clinical manifestations were graft dysfunction and fever.
  • In the majority of patients included in this review, the diagnosis was established from the tissue of explanted allograft.
  • Seven patients were diagnosed with B-cell lymphoma, and the relationship with Epstein-Barr virus could only be demonstrated in four patients.
  • However, the outcome was satisfactory in all cases, except in one case in which death was not related with the lymphoma etiology.
  • Health care providers should be aware of this clinical entity and heightened index of suspicion should be used so as not to delay diagnosis and not to lose the allograft.
  • [MeSH-major] Epstein-Barr Virus Infections / virology. Kidney Neoplasms / virology. Kidney Transplantation. Lymphoma, Large B-Cell, Diffuse / virology


45. Marks DI, Paietta EM, Moorman AV, Richards SM, Buck G, DeWald G, Ferrando A, Fielding AK, Goldstone AH, Ketterling RP, Litzow MR, Luger SM, McMillan AK, Mansour MR, Rowe JM, Tallman MS, Lazarus HM: T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). Blood; 2009 Dec 10;114(25):5136-45
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993).
  • The biology and outcome of adult T-cell acute lymphoblastic leukemia are poorly understood.
  • We present here the clinical and biologic features of 356 patients treated uniformly on the prospective trial (UKALL XII/ECOG 2993) with the aim of describing the outcome and identifying prognostic factors.
  • Central nervous system involvement at diagnosis did not affect survival (47% vs 48%, P = not significant).
  • This study provides a baseline for trials of new drugs, such as nelarabine, and may allow risk-adapted therapy in patients with poor-prognosis T-cell ALL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation / methods. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Immunol Methods. 2000 Sep 21;243(1-2):59-75 [10986407.001]
  • [Cites] J Clin Oncol. 2009 Sep 10;27(26):4352-6 [19635999.001]
  • [Cites] Hematol Oncol Clin North Am. 2002 Apr;16(2):245-99, v [12094473.001]
  • [Cites] Arch Pathol Lab Med. 2003 Jan;127(1):42-8 [12521365.001]
  • [Cites] Best Pract Res Clin Haematol. 2003 Dec;16(4):671-83 [14592650.001]
  • [Cites] Lancet. 2004 Feb 14;363(9408):535-6 [14975618.001]
  • [Cites] Blood. 2004 Jul 15;104(2):558-60 [15044257.001]
  • [Cites] Blut. 1990 Jan;60(1):48-51 [2297585.001]
  • [Cites] Cancer Genet Cytogenet. 1991 Mar;52(1):79-84 [2009514.001]
  • [Cites] Leukemia. 1996 Nov;10(11):1832-3 [8892689.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3028-37 [15256423.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] Blood. 2006 Jan 15;107(2):473-9 [16179376.001]
  • [Cites] Blood. 2006 Feb 1;107(3):1116-23 [16195338.001]
  • [Cites] Bone Marrow Transplant. 2006 Jun;37(11):989-95 [16633362.001]
  • [Cites] Blood. 2006 Jul 15;108(2):465-72 [16556888.001]
  • [Cites] Blood. 2007 Feb 1;109(3):910-5 [17023577.001]
  • [Cites] Blood. 2007 Feb 1;109(3):944-50 [17032921.001]
  • [Cites] Leukemia. 2007 Apr;21(4):604-11 [17287850.001]
  • [Cites] Leukemia. 2007 Apr;21(4):622-6 [17301806.001]
  • [Cites] Blood. 2007 Apr 15;109(8):3189-97 [17170120.001]
  • [Cites] J Clin Oncol. 2007 Aug 20;25(24):3739-45 [17646667.001]
  • [Cites] Blood. 2008 Feb 15;111(4):1827-33 [18048644.001]
  • [Cites] Nature. 2008 Apr 10;452(7188):764-7 [18401411.001]
  • [Cites] Br J Haematol. 2008 Oct;143(2):153-68 [18691165.001]
  • [Cites] Blood. 2009 Jan 1;113(1):100-7 [18838613.001]
  • [Cites] Blood. 2009 Apr 23;113(17):3918-24 [19109228.001]
  • [Cites] Haematologica. 2001 Jul;86(7):675-92 [11454522.001]
  • (PMID = 19828704.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137686856; United Kingdom / Medical Research Council / / G8223452; United Kingdom / Medical Research Council / / G0500389; United States / NCI NIH HHS / CA / R01CA120196; United States / NCI NIH HHS / CA / R01 CA120196; United States / NCI NIH HHS / CA / U24 CA114737; United States / NCI NIH HHS / CA / R01 CA120196-03
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.7.10.2 / Fusion Proteins, bcr-abl
  • [Other-IDs] NLM/ PMC2792210
  •  go-up   go-down


46. Nicholson E, Holyoake T: The chronic myeloid leukemia stem cell. Clin Lymphoma Myeloma; 2009;9 Suppl 4:S376-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The chronic myeloid leukemia stem cell.
  • Chronic myeloid leukemia (CML) is a clonal stem cell disorder that is characterized by the acquired chromosomal translocation BCR-ABL.
  • This gives rise to a constitutively active tyrosine kinase deregulation of the normal mechanisms of cell cycle control.
  • In the normal hematopoietic system, hematopoietic stem cells (HSC) self-renew to form identical daughter cells but also differentiate to mature blood cells.
  • Leukemic stem cells (LSC) share these properties of self-renewal and also differentiate to mature leukemic cells.
  • LSC have been isolated from patients with CML: these cells give rise to leukemia following transplantation into NOD-SCID mice models.
  • Further characterization of CML stem cells has demonstrated that a small percentage of these cells are quiescent despite culture with growth factors.
  • The CML stem cell arises from a normal HSC that has acquired the Philadelphia chromosome.
  • In advanced phase, more mature cells such as granulocyte/monocyte progenitors might also acquire the ability to self-renew and function as LSC.
  • Quiescent stem cells are resistant to treatment with imatinib in vitro and are thought also to show resistance in vivo.
  • The properties of the stem cells that lead to this drug resistance are still being characterized.
  • However, this drug insensitivity leads to disease persistence that may lead to disease relapse even despite an initial response to imatinib.
  • Newer molecular therapies are in development that act to specifically target and eradicate the stem cell pool.
  • [MeSH-major] Hematopoietic Stem Cells / pathology. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / diagnosis. Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy. Neoplastic Stem Cells / pathology
  • [MeSH-minor] Animals. Drug Resistance, Neoplasm. Humans. Mice


47. Zhao WL, Wang L, Liu YH, Yan JS, Leboeuf C, Liu YY, Wu WL, Janin A, Chen Z, Chen SJ: Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis. Exp Hematol; 2007 Dec;35(12):1801-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined effects of histone deacetylase inhibitor and rituximab on non-Hodgkin's B-lymphoma cells apoptosis.
  • OBJECTIVE: The anti-CD20 monoclonal antibody rituximab has shown promising results in the clinical treatment of patients with B-cell non-Hodgkin's lymphoma (B-NHL).
  • METHODS: This study examined the anti-tumor activity of rituximab combined with histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) in CD20-positive B-NHL cell lines, as well as in primary B-NHL cells and a murine B-NHL model.
  • RESULTS: The combination treatment sensitized B-NHL cells to apoptosis in a synergistic manner, concomitant with mitochondrial instability and Bcl-2/Bcl-XL downregulation.
  • Particularly in Daudi cells relatively resistant to rituximab, these events were associated with nuclear factor-kappaB (NF-kappaB) inactivation and c-Myc degradation.
  • More importantly, rituximab-SAHA combination significantly promoted primary B-NHL cells apoptosis and improved survival time of a severe combined immunodeficient mouse lymphoma model established with intravenous injection of Daudi cells.
  • CONCLUSION: These findings emphasized the value of targeting apoptosis signaling pathway in lymphoma therapy.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antineoplastic Agents / pharmacology. Apoptosis / drug effects. Enzyme Inhibitors / pharmacology. Histone Deacetylase Inhibitors. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Antibodies, Monoclonal, Murine-Derived. Base Sequence. Cell Line, Tumor. DNA Primers. Enzyme-Linked Immunosorbent Assay. Humans. Reverse Transcriptase Polymerase Chain Reaction. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17681667.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / DNA Primers; 0 / Enzyme Inhibitors; 0 / Histone Deacetylase Inhibitors; 4F4X42SYQ6 / Rituximab
  •  go-up   go-down


48. Kuper-Hommel MJ, Snijder S, Jansen-Heijnen ML, Vreugdenhil A, Noordijk EM, Kluin-Nelemans HC, Coebergh JW, van Krieken JH: Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews. Clin Lymphoma Myeloma; 2005 Nov;6(3):240-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment and survival of patients with thyroid lymphoma: a population-based study with clinical and pathologic reviews.
  • PURPOSE: The purpose of this study was to determine the incidence, clinical and histologic features, and patterns of outcome of thyroid lymphomas.
  • PATIENTS AND METHODS: A retrospective population-based survey of 38 patients with thyroid lymphoma was taken.
  • The most common subtype was diffuse large B-cell lymphoma (DLBCL; 63%) followed by extranodal marginal zone lymphoma (ENMZL; 29%).
  • At diagnosis, 22 patients (58%) had localized disease, and 41% had low-risk international prognostic index scores.
  • A complete clinical response was exhibited in 64% of patients, 14% exhibited a partial response, and 22% developed progressive disease.
  • At a median follow-up of 43 months (range, 0-240 months), 15 patients had relapsed or developed progressive disease.
  • Two-year overall survival rate was 59% for all patients, 68% for patients with localized disease, and 47% for patients with disseminated lymphoma.
  • CONCLUSION: Many thyroid lymphomas have clinical and histologic features characteristic of ENMZL and belong to this specific clinicopathologic entity.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Thyroid Neoplasms / pathology. Thyroid Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16354330.001).
  • [ISSN] 1557-9190
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


49. Utsunomiya A, Ishida T, Inagaki A, Ishii T, Yano H, Komatsu H, Iida S, Yonekura K, Takeuchi S, Takatsuka Y, Ueda R: Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor. Leuk Res; 2007 Jul;31(7):915-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical significance of a blood eosinophilia in adult T-cell leukemia/lymphoma: a blood eosinophilia is a significant unfavorable prognostic factor.
  • We investigated the clinical significance of a blood eosinophilia in a cohort of 158 consecutive patients with adult T-cell leukemia/lymphoma (ATLL), and multivariate analysis revealed that a blood eosinophilia was an independent and a significant unfavorable prognostic factor.
  • [MeSH-major] Eosinophilia / diagnosis. Leukemia-Lymphoma, Adult T-Cell / diagnosis
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Biomarkers / blood. Cohort Studies. Eosinophils / pathology. Female. Humans. L-Lactate Dehydrogenase / blood. Leukocyte Count. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Eosinophilic Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17123603.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


50. Cheng M, Ott GR: Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma. Anticancer Agents Med Chem; 2010 Mar;10(3):236-49
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase as a therapeutic target in anaplastic large cell lymphoma, non-small cell lung cancer and neuroblastoma.
  • Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was originally identified as the oncogenic NPM (nucleophosmin)-ALK fusion protein due to a t (2;5) chromosomal translocation in anaplastic large cell lymphomas.
  • The recent reports of EML4 (echinoderm microtubule-associated protein-like 4)-ALK oncogenic proteins in non-small cell lung cancer (NSCLC) and the identification of ALK activating point mutations and gene amplification in neuroblastoma have indicated ALK as a potential major therapeutic target for human cancers.
  • Several small molecule ALK inhibitors from distinctive chemical scaffolds in either clinical or preclinical development stage are highlighted and profiled.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy. Lymphoma, Large-Cell, Anaplastic / drug therapy. Neuroblastoma / drug therapy. Protein-Tyrosine Kinases / antagonists & inhibitors


51. Hornberger JC, Best JH: Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer; 2005 Apr 15;103(8):1644-51
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma.
  • BACKGROUND: Findings from the Groupe d'Etude des Lymphomes Adultes LNH 98-5 study showed that rituximab added to combined cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) prolonged progression-free survival and overall survival in adults age >/= 60 years with diffuse large B-cell non-Hodgkin lymphoma (DLBCL).
  • METHODS: Clinical prognosis of the time to disease progression and death was estimated using published evidence from the LNH 98-5 study (n = 399 patients) that was linked mathematically to published long-term outcome data on patients with DLBCL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / economics. Drug Costs. Lymphoma, B-Cell / economics. Lymphoma, Large B-Cell, Diffuse / economics
  • [MeSH-minor] Aged. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / economics. Antibodies, Monoclonal, Murine-Derived. Costs and Cost Analysis. Cyclophosphamide / administration & dosage. Cyclophosphamide / economics. Disease Progression. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / economics. Humans. Mathematics. Middle Aged. Prednisone / administration & dosage. Prednisone / economics. Quality of Life. Rituximab. Survival Rate. Time Factors. United States. Vincristine / administration & dosage. Vincristine / economics

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 15756658.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


52. Seegmiller AC, Karandikar NJ, Kroft SH, McKenna RW, Xu Y: Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes. Cytometry B Clin Cytom; 2009 May;76(3):169-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overexpression of CD7 in classical Hodgkin lymphoma-infiltrating T lymphocytes.
  • BACKGROUND: Diagnosis of Hodgkin lymphoma (HL) is sometimes complicated by the scarcity of neoplastic cells in a reactive inflammatory background.
  • Immunophenotyping by flow cytometry (FC) has not played a significant role in HL diagnosis because of its consistent failure to identify these neoplastic cells.
  • However, HL-infiltrating T cells have been shown to play a role in HL pathogenesis.
  • This study characterizes the FC immunophenotype of these T lymphocytes to determine whether they can be used to assist in the diagnosis of HL.
  • METHODS: Cell suspensions from 76 lymph nodes involved by HL and 156 lymph nodes with reactive lymphadenopathy (LAD) were analyzed by flow cytometry to assess the expression of T-cell antigens.
  • RESULTS: The CD4:CD8 ratio and CD7 expression in both CD4(+) and CD8(+) T cells are increased in HL compared with reactive lymph nodes and there are significant differences between these features in different subtypes of HL.
  • However, only the expression of CD7 in CD4(+) T cells distinguishes between HL and reactive LAD.
  • CONCLUSIONS: There are significant differences in the immunophenotypes of HL-infiltrating T cells.
  • Of these, the CD7 expression in CD4(+) T cells discriminates between HL and reactive LAD, suggesting that this could be a useful and practical adjunctive tool in the diagnosis of HL.
  • It may also further our understanding of the pathophysiology of this disease.
  • [MeSH-major] Antigens, CD7 / biosynthesis. CD4-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / metabolism. Hodgkin Disease / metabolism. Lymphocytes, Tumor-Infiltrating / metabolism. T-Lymphocyte Subsets / metabolism

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Clinical Cytometry Society.
  • [CommentIn] Cytometry B Clin Cytom. 2010 Nov;78(6):387-8 [20533387.001]
  • (PMID = 18956470.001).
  • [ISSN] 1552-4957
  • [Journal-full-title] Cytometry. Part B, Clinical cytometry
  • [ISO-abbreviation] Cytometry B Clin Cytom
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD3; 0 / Antigens, CD4; 0 / Antigens, CD7; 0 / Antigens, CD8
  •  go-up   go-down


53. Savio A: [The gastric MALT lymphoma. An unforeseen model for studying the pathogenesis of the lymphomas]. Recenti Prog Med; 2009 Jun;100(6):311-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The gastric MALT lymphoma. An unforeseen model for studying the pathogenesis of the lymphomas].
  • [Transliterated title] Il linfoma gastrico MALT: un sorprendente modello di studio per la comprensione della genesi dei linfomi.
  • MALT lymphoma is a low-grade lymphoma originating from the mucosa associated lymphoid tissue.
  • It is the third most frequent non-Hodgkin B-cell lymphomas.
  • The causal association between Helicobacter pylori infection and gastric MALT lymphoma is proved by numerous clinical and experimental studies.
  • The most dramatic evidence supporting a pathogenetic role for H. pylori in gastric MALT lymphoma is remission of the tumour following eradication with antibiotic therapy.
  • However, the evolution of a H. pylori infection towards lymphoma is an exceptional event which takes place probably due to the concurrence of host, environmental and bacterial strain factors.
  • Gastric MALT lymphoma is currently the only malignant neoplasia that can be cured by a simple antibiotic therapy.
  • Surgical treatment of this disease has been completely abandoned.
  • The role of chemio and radiotherapy is limited to the few cases non-responders to the antibiotic therapy.
  • This paper offers a wide and updated review of the literature about gastric MALT lymphoma.
  • Practical points for the clinical management are also given, in keeping with the European Guidelines that will be shortly published.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / etiology. Stomach Neoplasms / etiology
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Clinical Protocols. Follow-Up Studies. Helicobacter Infections / complications. Helicobacter pylori. Humans. Lymphoma / microbiology

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19708303.001).
  • [ISSN] 0034-1193
  • [Journal-full-title] Recenti progressi in medicina
  • [ISO-abbreviation] Recenti Prog Med
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 53
  •  go-up   go-down


54. Omoti CE, Omoti AE: Richter syndrome: a review of clinical, ocular, neurological and other manifestations. Br J Haematol; 2008 Sep;142(5):709-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Richter syndrome: a review of clinical, ocular, neurological and other manifestations.
  • Richter syndrome describes the development of high-grade non-Hodgkin lymphoma (NHL) or Hodgkin lymphoma in patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).
  • The large cell lymphoma clone occurs by transformation of the original CLL clone in the majority of patients, and as a separate and independent neoplasm in fewer cases.
  • These abnormalities may cause CLL cells to proliferate and, by facilitating the acquisition of new genetic abnormalities, to transform into Richter syndrome cells.
  • Presenting features typically include a rapid clinical deterioration with fever in the absence of infection, progressive lymph node enlargement, and an elevation in serum lactate dehydrogenase.
  • The therapeutic options include cytoreductive therapy consisting of chemotherapy and immunotherapy, followed by allogeneic stem cell transplantation as postremission therapy.
  • [MeSH-major] Hodgkin Disease. Lymphoma, Non-Hodgkin
  • [MeSH-minor] Central Nervous System Diseases / etiology. Eye Diseases / etiology. Gastrointestinal Diseases / etiology. Humans. Leukemia, Lymphocytic, Chronic, B-Cell / complications. Syndrome

  • Genetic Alliance. consumer health - Richter syndrome.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Br J Haematol. 2009 Feb;144(4):613; author reply 614-5 [19016718.001]
  • (PMID = 18492119.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 62
  •  go-up   go-down


55. Xu D: Dual surface immunoglobulin light-chain expression in B-cell lymphoproliferative disorders. Arch Pathol Lab Med; 2006 Jun;130(6):853-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dual surface immunoglobulin light-chain expression in B-cell lymphoproliferative disorders.
  • There have been several reports indicating that double light-chain gene rearrangements or dual light-chain expression can occur in B-cell malignant neoplasms, including chronic lymphocytic leukemia.
  • Currently, it is a common notion that demonstration of light-chain restriction in a B-cell population is generally considered proof of monoclonality and indicates malignancy.
  • OBJECTIVE: To increase awareness of the existence of the dual kappa/lambda immunoglobulin light-chain expressing B-cell leukemia/lymphoma, to emphasize the importance of visual inspection of flow cytometric data, and to present the guidelines for flow cytometric interpretation of dual kappa/lambda coexpressing populations.
  • DATA SOURCES: Through comprehensive literature review, this article discusses the current understandings regarding the dual light-chain expression in B-cell neoplasms, the cellular and molecular mechanisms, and the clinical and diagnostic implications of dual light-chain expression.
  • CONCLUSIONS: Dual kappa/lambda light-chain expressing B-cell leukemia/lymphomas do exist.
  • Recognition of the dual kappa/lambda light-chain expression on B cells has diagnostic implication in leukemia/lymphoma immunophenotyping.
  • [MeSH-minor] Biomarkers, Tumor / metabolism. Clone Cells. Flow Cytometry. Gene Rearrangement, B-Lymphocyte, Light Chain. Guidelines as Topic. Humans

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16740039.001).
  • [ISSN] 1543-2165
  • [Journal-full-title] Archives of pathology & laboratory medicine
  • [ISO-abbreviation] Arch. Pathol. Lab. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Immunoglobulin kappa-Chains; 0 / Immunoglobulin lambda-Chains
  • [Number-of-references] 17
  •  go-up   go-down


56. Shen L, Alam-Fotias S, Mansberg R, Nguyen D, Bui C: Subcutaneous panniculitis-like T cell lymphoma demonstrated on gallium-67 scintigraphy. Clin Nucl Med; 2005 Jul;30(7):500-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Subcutaneous panniculitis-like T cell lymphoma demonstrated on gallium-67 scintigraphy.
  • [MeSH-major] Citrates. Gallium. Lymphoma, T-Cell / radionuclide imaging. Panniculitis / radionuclide imaging. Skin Neoplasms / radionuclide imaging
  • [MeSH-minor] Diagnosis, Differential. Humans. Male. Middle Aged. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. GALLIUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15965330.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Citrates; 0 / Radiopharmaceuticals; 27905-02-8 / gallium citrate; CH46OC8YV4 / Gallium
  •  go-up   go-down


57. van Galen JC, Muris JJ, Giroth CP, Vos W, Ossenkoppele GJ, Meijer CJ, Oudejans JJ: Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas. Histopathology; 2008 Apr;52(5):578-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of TNF-receptor associated factor 2 correlates with poor progression-free survival time in ABC-like primary nodal diffuse large B-cell lymphomas.
  • AIMS: Tumour necrosis factor (TNF)-receptor associated factor 2 (TRAF2) is an adaptor molecule involved in nuclear factor (NF)-kappaB activation, which is characteristic of in vitro activated B-cell (ABC)-like diffuse large B-cell lymphomas (DLBCL) and may result in expression of anti-apoptotic genes and poor response to chemotherapy.
  • The aim was to determine whether TRAF2 is preferentially expressed in ABC-like DLBCL, and whether expression correlates with clinical outcome.
  • [MeSH-major] B-Lymphocytes / metabolism. Lymphoma, Large B-Cell, Diffuse / metabolism. TNF Receptor-Associated Factor 2 / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Fluorescent Antibody Technique, Direct. Germinal Center / pathology. Humans. Immunoenzyme Techniques. Male. Middle Aged. Prednisone / therapeutic use. Radiotherapy, Adjuvant. Survival Rate. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18312353.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / TNF Receptor-Associated Factor 2; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


58. Lawrie CH, Soneji S, Marafioti T, Cooper CD, Palazzo S, Paterson JC, Cattan H, Enver T, Mager R, Boultwood J, Wainscoat JS, Hatton CS: MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma. Int J Cancer; 2007 Sep 01;121(5):1156-61
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.
  • Diffuse large B cell lymphoma (DLBCL) is an aggressive malignancy that accounts for nearly 40% of all lymphoid tumors.
  • This heterogeneous disease can be divided into germinal center B cell-like (GCB) and activated B cell-like (ABC) subtypes by gene expression and immunohistochemical profiling.
  • Using microarray analysis on prototypic cell lines, we identified microRNAs (miR-155, miR-21 and miR-221) that were more highly expressed in ABC-type than GCB-type cell lines.
  • These microRNAs were over-expressed in de novo DLBCL (n = 35), transformed DLBCL (n = 14) and follicular center lymphoma cases (n = 27) compared to normal B cells.
  • Consistent with the cell line model, expression levels were higher in DLBCL cases with an ABC-type immunophenotype than those that were GCB-type (p < 0.05).
  • Moreover, using multivariate analysis we found that expression of miR-21 was an independent prognostic indicator in de novo DLBCL (p < 0.05).
  • Interestingly, expression levels of both miR-155 and miR-21 were also higher in nonmalignant ABC than in GCB cells.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology. MicroRNAs / genetics
  • [MeSH-minor] Cell Line, Tumor. Disease-Free Survival. Humans. Prognosis. Regression Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17487835.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Grant] United Kingdom / Medical Research Council / / MC/ U137973817
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  •  go-up   go-down


59. Martinelli G, Gigli F, Calabrese L, Ferrucci PF, Zucca E, Crosta C, Pruneri G, Preda L, Piperno G, Gospodarowicz M, Cavalli F, Moreno Gomez H: Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected]. Leuk Lymphoma; 2009 Jun;50(6):925-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early stage gastric diffuse large B-cell lymphomas: results of a randomized trial comparing chemotherapy alone versus chemotherapy + involved field radiotherapy. (IELSG 4). [corrected].
  • Here, we present the results of a randomised clinical trial carried out between 1998 and 2004, evaluating the possible role of radiotherapy (RT) as consolidation treatment after induction chemotherapy (CT) in diffuse large B-cell (DLBC) gastric lymphoma.
  • Clinical results of patients allocated to the RT arm showed a significant reduction in incidence of local relapse versus patients who received CT alone.
  • Our results confirm that CT could be considered as first line therapy for newly diagnosed gastric DLBC lymphoma; IF RT delivered in those patients achieving CR after induction CT is able to prevent local relapse.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Stomach Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy / adverse effects. Female. Humans. Male. Middle Aged. Nausea / etiology. Neoplasm Staging. Neutropenia / etiology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Leuk Lymphoma. 2010 Apr;51(4):733
  • [ErratumIn] Leuk Lymphoma. 2009 Nov;50(11):1904
  • (PMID = 19479614.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  •  go-up   go-down


60. Besson C, Canioni D, Lepage E, Pol S, Morel P, Lederlin P, Van Hoof A, Tilly H, Gaulard P, Coiffier B, Gisselbrecht C, Brousse N, Reyes F, Hermine O, Groupe d'Etude des Lymphomes de l'Adulte Programs: Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs. J Clin Oncol; 2006 Feb 20;24(6):953-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Characteristics and outcome of diffuse large B-cell lymphoma in hepatitis C virus-positive patients in LNH 93 and LNH 98 Groupe d'Etude des Lymphomes de l'Adulte programs.
  • PURPOSE: Epidemiologic studies show an association between hepatitis C virus (HCV) and B-cell non-Hodgkin's lymphoma (NHL).
  • Treatment and outcome of patients with diffuse large-cell lymphoma (DLCL) and HCV infection are still a matter of debate.
  • PATIENTS AND METHODS: We studied the HCV-positive patients with B-cell DLCL included in the Groupe d'Etude des Lymphomes de l'Adulte (GELA) programs LNH 93 and LNH 98.
  • RESULTS: Histologic types of HCV-positive DLCL were more frequently transformed from low-grade lymphoma than DLCL in HCV-negative patients (32% v 6%, P = .02).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hepatitis C / complications. Hepatitis C Antigens / blood. Liver / drug effects. Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adult. Aged. Antiviral Agents / therapeutic use. Disease-Free Survival. Female. Humans. Immunohistochemistry. Incidence. Male. Middle Aged. Seroepidemiologic Studies. Severity of Illness Index. Spleen / pathology. Spleen / virology. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2006 Jul 20;24(21):3513; author reply 3513-4 [16849775.001]
  • (PMID = 16418500.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / Hepatitis C Antigens
  •  go-up   go-down


61. Willenbrock K, Bräuninger A, Hansmann ML: Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases. Br J Haematol; 2007 Sep;138(6):733-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Frequent occurrence of B-cell lymphomas in angioimmunoblastic T-cell lymphoma and proliferation of Epstein-Barr virus-infected cells in early cases.
  • Secondary lymphomas occurring in the setting of angioimmunoblastic T-cell lymphoma (AILT) are considered to be rare.
  • A previous study detected a dysregulated hypermutation process in B-cells of AILT.
  • The present study aimed at estimating the frequency of B-cell lymphomas in AILT.
  • By studying the expression of EBV and activation-induced cytidine deaminase (AID) as an indicator of hypermutating cells, we assessed whether B-cell lymphoproliferations in AILT were strictly associated with EBV and whether hypermutation might contribute to lymphomagenesis.
  • Among 161 cases of AILT, diagnosed between 1996 and 2005 at the lymph node registry, Frankfurt, Germany, 19 cases were detected that also had B-cell non-Hodgkin lymphoma (NHL) and two cases had classical Hodgkin lymphoma (HL).
  • EBV was detected in tumour cells of 7/18 NHL and both HL, suggesting that factors other than EBV contribute to lymphomagenesis.
  • AID was expressed in AILT in large cells disseminated in the tissue, implying that the process of somatic hypermutation is ongoing in AILT, although the GC architecture is disrupted.
  • This might be relevant in the development of secondary lymphomas.
  • [MeSH-major] Epstein-Barr Virus Infections / pathology. Herpesvirus 4, Human. Lymphoma, B-Cell / virology. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] B-Lymphocytes / pathology. Biomarkers, Tumor / analysis. Cell Proliferation. Clone Cells. Cytidine Deaminase / analysis. DNA-Binding Proteins / analysis. Gene Rearrangement, B-Lymphocyte. Humans. Immunohistochemistry. In Situ Hybridization. Neprilysin / analysis. Polymerase Chain Reaction / methods. RNA, Viral / analysis. Somatic Hypermutation, Immunoglobulin. T-Lymphocytes / pathology

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17672882.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BCL6 protein, human; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / RNA, Viral; EC 3.4.24.11 / Neprilysin; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


62. Fraga M, Forteza J: Diagnosis of Hodgkin's disease: an update on histopathological and immunophenotypical features. Histol Histopathol; 2007 08;22(8):923-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnosis of Hodgkin's disease: an update on histopathological and immunophenotypical features.
  • The Hodgkin lymphoma (HL) is a B-cell lymphoma, as was proved by molecular studies with single-cell PCR.
  • Histologically, it is characterized by a minority of neoplastic cells, Reed-Sternberg cells and its variants, related to a variable non-neoplastic inflammatory background.
  • Nowadays, (WHO classification) the following types of HL are recognized: Nodular Paragranuloma and the Classical Hodgkin Lymphoma, the latter including Nodular Sclerosis, Mixed Cellularity, Lymphocyte-rich Classical Hodgkin Lymphoma and Lymphocyte Depletion.
  • Morphology together with immunohistochemical studies allows to classify the different forms of Hodgkin lymphoma and to make a differential diagnosis with non-Hodgkin lymphomas.
  • All classical Hodgkin lymphomas are treated similarly, and chances for remission and survival are currently good.
  • [MeSH-major] Hodgkin Disease / diagnosis. Immunophenotyping. Lymphoma, Non-Hodgkin / diagnosis. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Animals. Diagnosis, Differential. Humans. Immunohistochemistry. Lymph Nodes / immunology. Lymph Nodes / pathology. Polymerase Chain Reaction. Prognosis. Receptors, Antigen / genetics

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17503349.001).
  • [ISSN] 1699-5848
  • [Journal-full-title] Histology and histopathology
  • [ISO-abbreviation] Histol. Histopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Receptors, Antigen
  • [Number-of-references] 122
  •  go-up   go-down


63. Ohshima R, Tomita N, Motohashi K, Ieda A, Hyou R, Fujisawa S, Fujita H, Sakai R, Koharazawa H, Kuwabara H, Kanamori H, Ishigatsubo Y: [Clinical course of 8 patients with intravascular large B-cell lymphoma diagnosed while alive]. Rinsho Ketsueki; 2005 Jun;46(6):453-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course of 8 patients with intravascular large B-cell lymphoma diagnosed while alive].
  • We retrospectively evaluated the diagnosis and clinical courses of 8 patients with intravascular large B-cell lymphoma (IVL) diagnosed while they were alive.
  • Most complaints at diagnosis were fever or dyspnea.
  • All patients were in clinical stage IV with B symptoms and 4 patients showed performance status 4.
  • The diagnosis of IVL was confirmed by biopsy specimens from the bone marrow in 4, lung in 2, muscle, adrenal gland, and lymph node in 1 case, respectively.
  • In suspicious cases, it is important to bear IVL in mind and examine bone marrow biopsies for an early diagnosis.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis. Vascular Neoplasms / diagnosis
  • [MeSH-minor] Aged. Aged, 80 and over. Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Early Diagnosis. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Rituximab

  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16447727.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab
  • [Number-of-references] 17
  •  go-up   go-down


64. Nagasaki A, Miyagi T, Taira T, Shinhama A, Kojya S, Suzuki M, Aonahata M, Yoshimi N, Takasu N: Adult T-cell leukemia/lymphoma with multiple integration of HTLV-1 provirus presenting as an isolated paranasal sinus tumor: a case report. Head Neck; 2008 Jun;30(6):815-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult T-cell leukemia/lymphoma with multiple integration of HTLV-1 provirus presenting as an isolated paranasal sinus tumor: a case report.
  • BACKGROUND: Adult T-cell leukemia/lymphoma (ATLL) is a highly aggressive T-cell lymphoma and etiologically associated with human T-lymphotropic virus type 1 (HTLV-1).
  • Thereafter, the patient showed an indolent clinical course with leukemic changes and pulmonary and cutaneous ATLL lesions and remains alive more than 5 years from diagnosis.
  • CONCLUSION: ATLL should be included in the differential diagnosis of sinonasal lymphoma, although the event is rare.
  • [MeSH-major] Human T-lymphotropic virus 1 / physiology. Leukemia-Lymphoma, Adult T-Cell / diagnosis. Paranasal Sinus Neoplasms / diagnosis. Proviruses / physiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18023035.001).
  • [ISSN] 1043-3074
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Kwak JY, Kim EK, Ko KH, Yang WI, Kim MJ, Son EJ, Oh KK, Kim KW: Primary thyroid lymphoma: role of ultrasound-guided needle biopsy. J Ultrasound Med; 2007 Dec;26(12):1761-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary thyroid lymphoma: role of ultrasound-guided needle biopsy.
  • OBJECTIVE: The purpose of this study was to describe the sonographic findings of primary thyroid lymphoma and evaluate the role of ultrasound-guided biopsy in diagnosing thyroid lymphoma.
  • We searched the database of our institution and retrospectively collected data on the thyroid lymphomas that were confirmed pathologically.
  • The most notable sonographic feature of primary thyroid lymphoma was a marked hypoechoic mass compared with the residual thyroid tissue.
  • Among the 6 patients with a diagnosis of thyroid lymphoma, 3 (50%) had a diagnosis of lymphoma by ultrasound-guided fine-needle aspiration biopsy.
  • Most patients with thyroid lymphoma (5/6 [83.3%]) were found to have diffuse large B-cell lymphoma and were treated with chemotherapy with or without radiotherapy.
  • In 1 patient with follicular lymphoma, diagnosis and treatment were accomplished by total thyroidectomy.
  • CONCLUSIONS: Our results show that ultrasound-guided core needle biopsy can be a safe and accurate method for diagnosing thyroid lymphoma and may be a suitable replacement for diagnostic thyroid surgery.
  • [MeSH-major] Biopsy, Needle / methods. Lymphoma / pathology. Lymphoma / ultrasonography. Surgery, Computer-Assisted / methods. Thyroid Neoplasms / pathology. Thyroid Neoplasms / ultrasonography. Ultrasonography, Interventional / methods

  • Genetic Alliance. consumer health - Thyroid Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18029928.001).
  • [ISSN] 0278-4297
  • [Journal-full-title] Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine
  • [ISO-abbreviation] J Ultrasound Med
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Choi YL, Suh YL, Kim D, Ko YH, Sung CO, Lee JI: Malignant lymphoma of the central nervous system: difficult histologic diagnosis after glucocorticoid therapy prior to biopsy. Clin Neuropathol; 2006 Jan-Feb;25(1):29-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant lymphoma of the central nervous system: difficult histologic diagnosis after glucocorticoid therapy prior to biopsy.
  • Four cases of central nervous system (CNS) lymphoma are reported which presented obstacles in diagnosis due to steroid treatment prior to biopsy.
  • Malignant lymphoma of the CNS may be indistinguishable from other conditions, even in view of the gravity of the diagnosis.
  • Characteristically, scattered degenerating small round cells with pyknotic or fragmented nuclei were also observed.
  • However, the molecular assessment of paraffin-embedded tissues revealed the monoclonal IgH gene rearrangement, which allowed the confident diagnosis of B cell lymphoma.
  • The histopathological findings of the present cases suggest that the tumor cells might be selectively destroyed by steroid treatment, which may render diagnosis impossible.
  • Thus, molecular genetic investigation constitutes an important tool for establishing a diagnosis of CNS lymphoma obscured by steroid administration.
  • This is especially true in cases where a paucity of tumor cells is observed or when monoclonality fails to be demonstrated by immunohistochemical tests.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Central Nervous System Neoplasms / drug therapy. Glucocorticoids / therapeutic use. Lymphoma / diagnosis. Lymphoma / drug therapy
  • [MeSH-minor] Aged. Dexamethasone / therapeutic use. Diagnosis, Differential. Female. Gene Rearrangement, B-Lymphocyte, Heavy Chain. Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor. Glioblastoma / pathology. Glioma / pathology. Humans. Male. Neoplasms, Neuroepithelial / pathology. Polymerase Chain Reaction

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16465772.001).
  • [ISSN] 0722-5091
  • [Journal-full-title] Clinical neuropathology
  • [ISO-abbreviation] Clin. Neuropathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Glucocorticoids; 7S5I7G3JQL / Dexamethasone
  •  go-up   go-down


67. Brown JR, Freedman AS: ASCT in follicular lymphoma. Nat Rev Clin Oncol; 2009 Jul;6(7):380-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ASCT in follicular lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Follicular / therapy. Stem Cell Transplantation / methods

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19561632.001).
  • [ISSN] 1759-4782
  • [Journal-full-title] Nature reviews. Clinical oncology
  • [ISO-abbreviation] Nat Rev Clin Oncol
  • [Language] eng
  • [Publication-type] News
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 7S5I7G3JQL / Dexamethasone; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


68. Laharanne E, Oumouhou N, Bonnet F, Carlotti M, Gentil C, Chevret E, Jouary T, Longy M, Vergier B, Beylot-Barry M, Merlio JP: Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol; 2010 Jun;130(6):1707-18
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes.
  • This study was undertaken to identify recurrent genetic alterations of the three main types of cutaneous T-cell lymphomas (CTCLs): mycosis fungoides (MF), Sézary syndrome (SS), and cutaneous anaplastic large-cell lymphoma (CALCL).
  • Such imbalances were statistically associated with one CTCL subtype.
  • Unsupervised hierarchical clustering defined three categories of clinical relevance:.
  • In rare cases, the genetic classification did not correspond to the inclusion diagnosis, possibly reflecting the association of two diseases in the same patient or initial misdiagnosis according to follow-up.
  • [MeSH-major] DNA, Neoplasm / genetics. Gene Expression Profiling. Lymphoma, T-Cell, Cutaneous / classification. Lymphoma, T-Cell, Cutaneous / genetics. Skin Neoplasms / classification. Skin Neoplasms / genetics
  • [MeSH-minor] Algorithms. Gene Expression Regulation, Neoplastic. Humans. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / genetics. Multigene Family / genetics. Mycosis Fungoides / diagnosis. Mycosis Fungoides / genetics. Oligonucleotide Array Sequence Analysis. Ploidies. Reproducibility of Results. Sezary Syndrome / diagnosis. Sezary Syndrome / genetics


69. Nückel H, Hüttmann A, Klein-Hitpass L, Schroers R, Führer A, Sellmann L, Dührsen U, Dürig J: Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia. Leuk Lymphoma; 2006 Jun;47(6):1053-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lipoprotein lipase expression is a novel prognostic factor in B-cell chronic lymphocytic leukemia.
  • B-cell chronic lymphocytic leukemia (B-CLL) is a heterogenous disease with a highly variable clinical course.
  • To investigate the prognostic value of these genes, we quantified their expression in peripheral blood mononuclear cells using quantitative reverse transcriptase-polymerase chain reaction (RQ-PCR) in a cohort of 133 B-CLL patients and correlated the results with clinical outcome, and other known prognostic factors.
  • Evaluation of several disease characteristics in association with the LPL expression status of the patients' B-CLL cells showed highly significant differences for CD38 and ZAP-70 expression, suggesting a correlation of LPL expression with these established adverse prognostic factors.
  • Furthermore, in a subgroup analysis, LPL provided prognostic information in both early stage (Binet A) and patients with more advanced disease (Binet B and C).
  • [MeSH-major] ADAM Proteins / biosynthesis. Gene Expression Regulation, Leukemic. Gene Expression Regulation, Neoplastic. Leukemia, Lymphocytic, Chronic, B-Cell / enzymology. Leukemia, Lymphocytic, Chronic, B-Cell / metabolism. Lipoprotein Lipase / biosynthesis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16840197.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.2 / ZAP-70 Protein-Tyrosine Kinase; EC 3.1.1.34 / Lipoprotein Lipase; EC 3.2.2.5 / Antigens, CD38; EC 3.4.24.- / ADAM Proteins; EC 3.4.24.- / ADAM29 protein, human
  •  go-up   go-down


70. Lee AM, Clear AJ, Calaminici M, Davies AJ, Jordan S, MacDougall F, Matthews J, Norton AJ, Gribben JG, Lister TA, Goff LK: Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome. J Clin Oncol; 2006 Nov 1;24(31):5052-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Number of CD4+ cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.
  • PURPOSE: To examine the immune microenvironment in diagnostic follicular lymphoma (FL) biopsies and evaluate its prognostic significance.
  • PATIENTS AND METHODS: Immunohistochemistry was used to study numbers and location of cells staining positive for immune cell markers CD4, CD7, CD8, CD25, CD68, forkhead box protein P3 (FOXP3), T-cell intracellular antigen-1, and Granzyme B in tissue microarrays of paraffin-embedded, diagnostic lymph node biopsies taken from 59 FL patients who lived less than 5 years (short-survival group; n = 34) and more than 15 years (long-survival group; n = 25).
  • Samples from the long-survival group were more likely than those from the short-survival group to have CD4+ staining cells and to have FOXP3-positive cells in a perifollicular location.
  • CONCLUSION: This study has identified differences in immune cell composition of the diagnostic FL lymph node immune microenvironment and these have the potential for use as prognostic biomarkers in a routine histopathology setting.
  • [MeSH-major] CD4-Positive T-Lymphocytes. Forkhead Transcription Factors / analysis. Lymphoma, Follicular / chemistry. Protein Array Analysis

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033038.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


71. Qiu JY, Zhu W, Zhang Y, Chen SS, Jiang B, Shi HL, Shi Y, He Q, Dang H, Wang DB, Lu DP: [Cytogenetic and clinical study of Philadelphia chromosome positive adult acute leukemia]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Jun;13(3):358-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytogenetic and clinical study of Philadelphia chromosome positive adult acute leukemia].
  • To explore the cytogenetics and related clinical characteristics of adult acute leukemia with Philadelphia chromosome positive (Ph(+)AL), MIC classification by morphology, immunology and cytogenetics was used to retrospectively study 79 patients with Ph(+)AL hospitalized in the Institute of Hematology, People Hospital in Beijing from October 1991 to September 2003.
  • B-cell antigen expression was found in 52 out of 56 patients with Ph(+)ALL.
  • It is concluded that Ph(+)AL has highly heterogeneity involving various differentiated stages of immature leukemic cells.
  • Since the poor prognosis associated with this kind of AL, early diagnosis with MIC classification is a prerequisite to take more effective conditioning regimen and prospectively consideration of allogeneic stem cell transplantation to improve prognosis.

  • MedlinePlus Health Information. consumer health - Acute Myeloid Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15972120.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


72. Zhao XF, Young KH, Frank D, Goradia A, Glotzbecker MP, Pan W, Kersun LS, Leahey A, Dormans JP, Choi JK: Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases. Am J Clin Pathol; 2007 Jan;127(1):47-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric primary bone lymphoma-diffuse large B-cell lymphoma: morphologic and immunohistochemical characteristics of 10 cases.
  • Most primary bone lymphomas (PBLs) are diffuse large B-cell lymphomas (DLBCLs).
  • They were diagnosed often after months to years of symptoms, suggesting an indolent disease.
  • Biopsy revealed that the lymphomas were paratrabecular or diffuse and were medium- to large-sized with round to irregular nuclei, dispersed chromatin, indistinct to small nucleoli, and abundant cytoplasm.
  • All cases marked as mature B cells, and most were CD10+ (7/10).
  • Typical centroblastic morphologic features with nucleoli were rare, multilobated nuclei were uncommon, and CD10 negativity did not predict poor prognosis, unlike in the adult PBL-DLBCL.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, B-Cell / pathology. Lymphoma, Large B-Cell, Diffuse / pathology

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17145622.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


73. Bethge WA, Lange T, Meisner C, von Harsdorf S, Bornhaeuser M, Federmann B, Stadler M, Uharek L, Stelljes M, Knop S, Wulf G, Trenschel R, Vucinic V, Dittmann H, Faul C, Vogel W, Kanz L, Bunjes D: Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study. Blood; 2010 Sep 9;116(10):1795-802
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy with yttrium-90-ibritumomab tiuxetan as part of a reduced- intensity conditioning regimen for allogeneic hematopoietic cell transplantation in patients with advanced non-Hodgkin lymphoma: results of a phase 2 study.
  • Forty patients were enrolled in this phase 2 study combining radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT) from related (n = 13) or unrelated (n = 27) donors for the treatment of advanced non-Hodgkin lymphoma.
  • Diagnoses were follicular lymphoma (n = 17), chronic lymphocytic leukemia (n = 13), mantle cell lymphoma (n = 8), marginal zone lymphoma (n = 1), and lymphoplasmacytic lymphoma (n = 1).
  • All patients were high risk with refractory disease or relapse after preceding autologous HCT.
  • Incidences of acute graft-versus-host disease 2-4 and chronic graft-versus-host disease were 43% and 53%, respectively.
  • Twenty-two of 40 patients (55%) are alive, resulting in a Kaplan-Meier-estimated 2-year survival of 51% for all, 67% for follicular lymphoma, 49% for chronic lymphocytic leukemia, and 37% for mantle cell lymphoma patients.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Lymphoma, Non-Hodgkin / radiotherapy. Lymphoma, Non-Hodgkin / surgery. Radioimmunotherapy / methods
  • [MeSH-minor] Adult. Aged. Antibodies, Monoclonal / chemistry. Combined Modality Therapy. Female. Graft vs Host Disease / etiology. Hematologic Diseases / etiology. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Transplantation Conditioning / methods. Transplantation, Homologous. Treatment Outcome. Yttrium Radioisotopes / chemistry. Yttrium Radioisotopes / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20530284.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT00302757
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Yttrium Radioisotopes; 0 / ibritumomab tiuxetan
  •  go-up   go-down


74. Diepstra A, van Imhoff GW, Karim-Kos HE, van den Berg A, te Meerman GJ, Niens M, Nolte IM, Bastiaannet E, Schaapveld M, Vellenga E, Poppema S: HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma. J Clin Oncol; 2007 Jul 20;25(21):3101-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
  • PURPOSE: The neoplastic Hodgkin Reed-Sternberg (HRS) cells in classical Hodgkin's lymphoma (cHL) are derived from B cells.
  • Median age at diagnosis was 38 years (range, 8 to 88 years); 63% had Ann Arbor stage I or II, 24% stage III, and 13% stage IV disease.
  • RESULTS: Lack of HLA class II cell-surface expression on HRS cells was observed in 41.4% and was more common in patients with extranodal disease, patients with Epstein-Barr virus-negative disease, and patients with HLA class I-negative HRS cells.
  • CONCLUSION: Lack of membranous HLA class II expression by HRS cells in diagnostic lymph node specimens is an independent adverse prognostic factor in cHL.
  • [MeSH-major] Biomarkers, Tumor / analysis. Cause of Death. Histocompatibility Antigens Class II / analysis. Hodgkin Disease / immunology. Hodgkin Disease / mortality. Reed-Sternberg Cells / immunology

  • Genetic Alliance. consumer health - Factor II Deficiency.
  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17536082.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Histocompatibility Antigens Class II
  •  go-up   go-down


75. Ahluwalia MS, Peereboom DM: Primary central nervous system lymphoma. Curr Treat Options Neurol; 2010 Jul;12(4):347-59
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system lymphoma.
  • OPINION STATEMENT: Management goals for patients with primary central nervous system lymphoma (PCNSL) include long-term disease control, management of neurologic complications, and preservation of neurocognitive function.
  • Outside of a clinical trial, patients with newly diagnosed PCNSL should receive high-dose intravenous methotrexate (MTX) as a single agent or as part of a combination regimen with radiation therapy reserved for relapse.
  • The regimen should have an adequate MTX dose (>3 g/m(2)) to reach cytotoxic concentrations in the cerebrospinal fluid (CSF) to treat occult leptomeningeal disease (LMD).
  • Alternative modes of chemotherapy delivery for selected patients, preferably in the context of a clinical trial, include high-dose chemotherapy with autologous stem cell rescue and intra-arterial chemotherapy with blood-brain barrier disruption.
  • However, lower doses in daily divided fractions may offer the possibility of adding this modality with preservation of cognition but should be performed only in the context of a clinical trial.
  • Patients with ocular lymphoma at diagnosis should receive high-dose MTX as this drug can reach cytotoxic intravitreal concentrations.
  • It is probably reasonable to withhold IT chemotherapy in those patients who have no detectable subarachnoid disease and who can receive higher doses of MTX (>3 g/m(2)) over shorter infusion periods (2-4 h).
  • Because PCNSL is an uncommon disease, entry into clinical trials must be pursued to advance the state of the art.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Ophthalmol. 2007 Sep;1(3):247-58 [19668478.001]
  • [Cites] Cancer. 2006 Jan 1;106(1):128-35 [16329140.001]
  • [Cites] J Neurooncol. 2009 Feb;91(3):299-305 [18931887.001]
  • [Cites] Neurosurgery. 2000 Jan;46(1):51-60; discussion 60-1 [10626935.001]
  • [Cites] Cancer. 2008 Sep 1;113(5):1025-31 [18618509.001]
  • [Cites] Neurology. 2007 Sep 11;69(11):1178-82 [17846417.001]
  • [Cites] J Clin Oncol. 2006 Oct 1;24(28):4570-4 [17008697.001]
  • [Cites] Neurology. 2008 Oct 21;71(17):1355-60 [18936428.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):635-43 [1548527.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):864-7 [17325700.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1507-13 [15735126.001]
  • [Cites] Clin Cancer Res. 2004 Sep 1;10(17):5643-6 [15355887.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):266-72 [12525518.001]
  • [Cites] Neurology. 2004 Sep 14;63(5):901-3 [15365145.001]
  • [Cites] Haematologica. 2008 Jan;93(1):147-8 [18166803.001]
  • [Cites] J Clin Oncol. 2000 Feb;18(3):519-26 [10653867.001]
  • [Cites] J Clin Oncol. 2007 Apr 10;25(11):1350-6 [17312328.001]
  • [Cites] J Clin Oncol. 2008 May 20;26(15):2512-8 [18413641.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4489-95 [14597744.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1992;23(1):9-17 [1572835.001]
  • [Cites] Eur J Haematol. 2003 Apr;70(4):219-24 [12656744.001]
  • [Cites] Neurology. 2000 Apr 25;54(8):1707-8 [10762527.001]
  • [Cites] J Clin Oncol. 2009 Jul 20;27(21):3503-9 [19451444.001]
  • [Cites] Neurology. 2005 Jan 11;64(1):69-74 [15642906.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):711-5 [12576439.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1561-7 [9552066.001]
  • [Cites] J Neurooncol. 2008 Jan;86(2):211-5 [17896078.001]
  • [Cites] Neuro Oncol. 2009 Apr;11(2):211-5 [18757775.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5711-5 [17116938.001]
  • [Cites] Ann Neurol. 2002 Feb;51(2):247-52 [11835382.001]
  • [Cites] J Neurooncol. 2006 Nov;80(2):159-65 [16699873.001]
  • [Cites] J Clin Oncol. 2002 Dec 15;20(24):4643-8 [12488408.001]
  • [Cites] Lancet. 2009 Oct 31;374(9700):1512-20 [19767089.001]
  • [Cites] J Clin Oncol. 1999 Oct;17(10):3110-6 [10506606.001]
  • [Cites] Cancer. 2007 Dec 1;110(11):2528-34 [17932895.001]
  • [Cites] Neurology. 2008 Jan 29;70(5):401-2 [18227422.001]
  • [Cites] Ann Oncol. 2006 Jul;17(7):1141-5 [16603598.001]
  • [Cites] J Clin Oncol. 2003 Mar 15;21(6):1044-9 [12637469.001]
  • [Cites] Neurology. 2002 May 28;58(10):1513-20 [12034789.001]
  • [Cites] Neurosurgery. 1980 Jul;7(1):36-43 [6774280.001]
  • [Cites] J Neurooncol. 2002 Jun;58(2):175-8 [12164690.001]
  • [Cites] J Clin Oncol. 2002 Jan 1;20(1):231-6 [11773174.001]
  • [Cites] Ann Neurol. 1995 Aug;38(2):202-9 [7654067.001]
  • [Cites] J Clin Oncol. 1998 Mar;16(3):859-63 [9508166.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3144-50 [10963643.001]
  • [Cites] Neurology. 2006 May 9;66(9):1435-8 [16682682.001]
  • [Cites] J Clin Oncol. 2003 Dec 15;21(24):4483-8 [14597741.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1462-9 [19224854.001]
  • [Cites] Arch Ophthalmol. 1997 Sep;115(9):1152-6 [9298056.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):809-13 [15936564.001]
  • [Cites] Leuk Lymphoma. 2003 Apr;44(4):627-33 [12769339.001]
  • [Cites] Eye (Lond). 2007 Dec;21(12):1524-7 [17464308.001]
  • [Cites] J Clin Oncol. 2007 Oct 20;25(30):4730-5 [17947720.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4151-6 [14615443.001]
  • (PMID = 20842593.001).
  • [ISSN] 1534-3138
  • [Journal-full-title] Current treatment options in neurology
  • [ISO-abbreviation] Curr Treat Options Neurol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


76. Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed. Prescrire Int; 2009 Feb;18(99):3-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine: new drug. T-lymphoblastic leukaemia/lymphoma: more evaluation needed.
  • 1) Acute T-lymphoblastic leukaemia and T-lymphoblastic lymphoma are closely related malignant haemopathies.
  • However, only haematopoietic stem cell transplantation following chemotherapy offers a chance of long-term survival;.
  • It is marketed for the treatment of children and adults with one or the other of these two malignant haemopathies, after failure of at least two lines of chemotherapy;.
  • 3) Clinical evaluation of nelarabine in this setting includes two non-comparative trials in accordance with the conditions of the marketing terms, one in 48 children and the other in 28 adults.
  • But this type of non-comparative trial cannot demonstrate whether a specific drug increases survival time compared with existing alternatives;.
  • 5) In practice, there are too many outstanding questions to determine whether nelarabine represents a therapeutic advance compared with clofarabine, or even whether it should be used outside the clinical trial setting.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adult. Child. Clinical Trials as Topic. Drug Approval. Europe. Humans. Orphan Drug Production. Recurrence

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19382393.001).
  • [ISSN] 1167-7422
  • [Journal-full-title] Prescrire international
  • [ISO-abbreviation] Prescrire Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Arabinonucleosides
  •  go-up   go-down


77. Avilés A, Nambo MJ, Neri N, Talavera A, Cleto S: Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol; 2005;22(1):57-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial.
  • We began a controlled clinical trial to evaluate efficacy and toxicity of the most common therapies.
  • Two hundred and forty-one patients with gastric low-grade MALT lymphoma in early stage (IE and IIE) were randomized to surgery (80 cases), radiotherapy (78 cases), and chemotherapy (83 cases).
  • No clear differences were observed between the most common therapies in patients with primary gastric MALT lymphoma in early stages, probably because this type of lymphoma has an high response rate to salvage treatment after failure to local treatment (surgery and radiotherapy).
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / therapy. Stomach Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2001 Sep 15;19(18):3874-83 [11559725.001]
  • [Cites] Lancet. 1995 Jun 24;345(8965):1591-4 [7783535.001]
  • [Cites] Aliment Pharmacol Ther. 2002 Oct;16(10 ):1715-22 [12269963.001]
  • [Cites] Am J Surg. 2000 Mar;179(3):216-22 [10827324.001]
  • [Cites] Cancer. 1999 Jan 1;85(1):9-17 [9921968.001]
  • [Cites] Ann Oncol. 2004 Jan;15(1):12-8 [14679113.001]
  • [Cites] Gut. 2003 Nov;52(11):1656 [14570741.001]
  • [Cites] Haematologica. 2000 Apr;85(4):372-80 [10756362.001]
  • [Cites] J Clin Oncol. 2003 Nov 15;21(22):4157-64 [14615444.001]
  • [Cites] Gastroenterology. 1997 May;112(5):1466-74 [9136823.001]
  • [Cites] Gastroenterology. 2000 Nov;119(5):1191-202 [11054376.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Mar 15;46(5):1093-103 [10725618.001]
  • [Cites] J Clin Pathol. 2000 Mar;53(3):187-90 [10823136.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Ann Oncol. 1994 May;5(5):397-400 [8075046.001]
  • [Cites] Ann Oncol. 1995 Apr;6(4):355-62 [7619750.001]
  • [Cites] Histopathology. 2002 Feb;40(2):117-26 [11952855.001]
  • [Cites] Gastroenterology. 1993 Dec;105(6):1662-71 [8253342.001]
  • [Cites] Gut. 2001 Mar;48(3):297-303 [11171816.001]
  • [Cites] Br J Cancer. 2000 Aug;83(4):454-7 [10945490.001]
  • (PMID = 15750197.001).
  • [ISSN] 1357-0560
  • [Journal-full-title] Medical oncology (Northwood, London, England)
  • [ISO-abbreviation] Med. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


78. Kusao I, Troelstrup D, Shiramizu B: Possible Mitochondria-Associated Enzymatic Role in Non-Hodgkin Lymphoma Residual Disease. Cancer Growth Metastasis; 2008 Nov 24;1:3-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible Mitochondria-Associated Enzymatic Role in Non-Hodgkin Lymphoma Residual Disease.
  • BACKGROUND: The mechanisms responsible for resistant or recurrent disease in childhood non-Hodgkin lymphoma (NHL) are not yet fully understood.
  • A unique mechanism suggesting the role of the mitochondria as the key energy source responsible for residual cells has been assessed in the clinical setting on specimens from patients on therapy were found to have increased copies of mitochondrial DNA (mtDNA) associated with positive minimal residual disease and/or persistent disease (MRD/PD) status.
  • This study hypothesized that in an in-vitro model, recovering or residual cells from chemotoxicity will exhibit an increase in both citrate synthase and isocitrate dehydrogenase expression and decrease in succinate dehydrogenase expression.
  • PROCEDURE: Ramos cells (Burkitt lymphoma cell line) were exposed to varying concentrations of doxorubicin and vincristine for 1 hr; and allowing for recovery in culture over a 7-day period. cDNA was extracted on days 1 and 7 of the cell culture period to assess the relative expression of the aforementioned genes.
  • RESULTS: Increase citrate synthase, increase isocitrate dehydrogenase and decrease succinate dehydrogenase expressions were found in recovering Ramos cells.
  • CONCLUSION: Recovering lymphoma cells appear to compensate by regulating enzymatic levels of appropriate genes in the Krebs Cycle suggesting an important role of the mitochondria in the presence of residual cells.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19936279.001).
  • [Journal-full-title] Cancer growth and metastasis
  • [ISO-abbreviation] Cancer Growth Metastasis
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R21 CA121955; United States / NCI NIH HHS / CA / CA121955-01; United States / NCI NIH HHS / CA / R21 CA121955-02
  • [Publication-type] JOURNAL ARTICLE
  • [Publication-country] United States
  •  go-up   go-down


79. Correa-González LC, Mandeville PB, Manrique-Dueñas J, Alejo-González F, Salazar-Martínez A, de Pérez-Ramírez OJ, Hernández-Sierra JF: [Prognostic value of pre-B immunophenotype in early treatment response among acute pediatric lymphoblast leukemia patients]. Gac Med Mex; 2005 Nov-Dec;141(6):477-82
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Valor pronóstico del inmunofenotipo en la respuesta temprana de la leucemia aguda linfoblástica pre-B en niños.
  • A panel of B, T, monoclonal antibodies of the myelo-monocytic and megakaryocytic cell type was used.
  • CONCLUSIONS: We need to pay special emphasis on early treatment response in children with lymphoblast leukemia as our study did not corroborate the common finding that clinical factors and immune phenotype can be predictive factors.
  • [MeSH-major] Leukemia, Lymphoid / drug therapy. Leukemia, Lymphoid / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology

  • MedlinePlus Health Information. consumer health - Chronic Lymphocytic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16381501.001).
  • [ISSN] 0016-3813
  • [Journal-full-title] Gaceta médica de México
  • [ISO-abbreviation] Gac Med Mex
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Mexico
  •  go-up   go-down


80. Bozas G, Anagnostou D, Tassidou A, Moulopoulos LA, Bamias A, Dimopoulos MA: Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature. Leuk Lymphoma; 2006 Feb;47(2):329-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extranodal non-Hodgkin's lymphoma presenting as an abdominal wall mass. A case report and review of the literature.
  • Soft tissue lymphoma is a very rare clinical entity with varying presentation characteristics and atypical clinical and imaging features.
  • The present report describes a patient who presented with a painless soft tissue mass on the posterolateral surface of the abdominal wall, simulating a neoplasm of mesenchymal origin.
  • After complete surgical excision, the tumor was diagnosed as a diffuse large B-cell lymphoma.
  • No B-symptoms were present and clinical staging did not reveal other sites of disease (stage I EA).
  • Post-operatively the patient was treated with immuno-chemotherapy consisting of rituximab plus cyclophosphamide, epirubicin, vincristine and prednisolone and is currently free of disease for 10 months.
  • The case is discussed with a brief review of the literature on the diagnosis, treatment and outcome of soft tissue lymphomas.
  • [MeSH-major] Abdominal Neoplasms / diagnosis. Abdominal Wall / pathology. Liposarcoma / diagnosis. Lymphoma, B-Cell / diagnosis. Lymphoma, Non-Hodgkin / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Diagnosis, Differential. Humans. Male. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321866.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Válková V, Trnený M: [The current role of haematopoietic stem cell transplantation in the treatment of lymphomas--review]. Klin Onkol; 2010;23(3):155-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The current role of haematopoietic stem cell transplantation in the treatment of lymphomas--review].
  • Despite the undeniable progress in first-line treatment, a significant proportion of patients with lymphoproliferative disease still relapse.
  • Autologous stem cell transplantation has for many years been the standard position in the treatment of chemosensitive relapse of diffuse large B cell lymphoma, Hodgkin's lymphoma and follicular lymphoma.
  • Recently, autologous stem cell transplantation has had significant importance in first-line therapy of some T-cell lymphoma and mantle cell lymphoma as well.
  • It is possible that this situation will change after the evaluation of clinical protocols using rituximab, either in first or second-line therapy or as part of the conditioning regimen and maintenance therapy.
  • In recent years, significant attention has also been focused on the identification of prognostic factors that could lead to earlier intensive therapy, including RIC-alo, particularly in mantle cell lymphoma, some T-cell lymphoma and Hodgkin's lymphoma.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20608325.001).
  • [ISSN] 0862-495X
  • [Journal-full-title] Klinická onkologie : casopis Ceské a Slovenské onkologické spolecnosti
  • [ISO-abbreviation] Klin Onkol
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 102
  •  go-up   go-down


82. Bayerl MG, Hennessy J, Ehmann WC, Bagg A, Rosamilia L, Clarke LE: Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma. J Cutan Pathol; 2010 Jul;37(7):777-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cutaneous monoclonal B-cell proliferations as harbingers of systemic angioimmunoblastic T-cell lymphoma.
  • We describe a 66-year-old man initially diagnosed with primary cutaneous marginal zone B-cell lymphoma who developed four additional monoclonal/monotypic B-cell lymphoid proliferations and a systemic angioimmunoblastic T-cell lymphoma over the course of 19 months.
  • Through retrospective analysis, we identified the evolution of a T-cell clone within the background of clinically and pathologically dominant cutaneous B-cell tumors.
  • In terms of clinical practice, this case supports that patients diagnosed with multiple clonal B-cell proliferation need thorough investigation and close clinical follow up to identify a coexistent or evolving systemic lymphoma, in particular, peripheral T-cell lymphomas of follicular T-helper cell type, such as angioimmunoblastic T-cell lymphoma.
  • Biologically, this case offers unique insight into the interactions between B-cell and T-cell lineages in lymphoid neoplasia.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / pathology. Lymphoma, T-Cell, Cutaneous / pathology. Neoplasms, Multiple Primary / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Male. Polymerase Chain Reaction. Receptors, Antigen, T-Cell / genetics

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19702684.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Immunoglobulin Heavy Chains; 0 / Receptors, Antigen, T-Cell
  •  go-up   go-down


83. Takata T, Suzumiya J, Ishikawa T, Takamatsu Y, Ikematsu H, Tamura K: Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP. J Clin Exp Hematop; 2009 May;49(1):9-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Attenuated antibody reaction for the primary antigen but not for the recall antigen of influenza vaccination in patients with non-Hodgkin B-cell lymphoma after the administration of rituximab-CHOP.
  • To assess the humoral response to the influenza vaccine in patients undergoing R-CHOP therapy (rituximab combined with cyclophosphamide, doxorubicin, vincristine, and predonisolone) for non-Hodgkin lymphoma (NHL), the anti-hemagglutinin (HA) titer in 7 NHL patients undergoing therapy was compared with those in 10 control group subjects in the 2005/2006 season.
  • Four weeks after vaccination, the HA titers against the influenza type A H1N1 and type B antigens, the same antigens that had been used in the previous seasons, were elevated in all patients treated with R-CHOP.
  • In contrast, there was no increase in the geometric mean titer for type A H3N2 antigen, which was newly included in 2005/2006 season, in the patients treated with R-CHOP, while there was a significant increase in the 10 control subjects (p = 0.014).
  • [MeSH-major] Antibodies, Monoclonal / administration & dosage. Influenza Vaccines / immunology. Lymphoma, B-Cell / drug therapy
  • [MeSH-minor] Adult. Aged. Antibodies / blood. Antibodies, Monoclonal, Murine-Derived. Antibody Formation. Antigens, Viral / immunology. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Case-Control Studies. Cyclophosphamide / therapeutic use. Doxorubicin / therapeutic use. Female. Hemagglutinins / immunology. Humans. Immunologic Memory. Influenza A Virus, H1N1 Subtype / immunology. Influenza A Virus, H3N2 Subtype / immunology. Male. Middle Aged. Pilot Projects. Prednisone / therapeutic use. Rituximab. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19474512.001).
  • [ISSN] 1880-9952
  • [Journal-full-title] Journal of clinical and experimental hematopathology : JCEH
  • [ISO-abbreviation] J Clin Exp Hematop
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antigens, Viral; 0 / Hemagglutinins; 0 / Influenza Vaccines; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


84. Kashima S, Alcantara LC, Takayanagui OM, Cunha MA, Castro BG, Pombo-de-Oliveira MS, Zago MA, Covas DT: Distribution of human T cell lymphotropic virus type 1 (HTLV-1) subtypes in Brazil: genetic characterization of LTR and tax region. AIDS Res Hum Retroviruses; 2006 Oct;22(10):953-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distribution of human T cell lymphotropic virus type 1 (HTLV-1) subtypes in Brazil: genetic characterization of LTR and tax region.
  • We report the molecular and epidemiological characterization of 128 human T cell lymphotropic virus type 1 (HTLV-1) isolates from Brazilian patients with different clinical manifestations of the infection.
  • Thirty-two percent of the patients were asymptomatic, 44% had HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), and 23% had adult T cell leukemia/lymphoma (ATLL).
  • Phylogenetic analysis performed using part of the LTR region of the viral genome revealed that all Brazilian isolates belonged to the Cosmopolitan subtype, with the following distribution within the Transcontinental subgroup: 81.6% within the Latin American cluster and 15.8% outside the Latin American cluster.
  • These changes were not correlated with a specific clinical status of the patients and could be a molecular characteristic of the HTLV-1 strains that circulate in Brazil.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17067264.001).
  • [ISSN] 0889-2229
  • [Journal-full-title] AIDS research and human retroviruses
  • [ISO-abbreviation] AIDS Res. Hum. Retroviruses
  • [Language] eng
  • [Databank-accession-numbers] GENBANK/ AB036346/ AB036368/ AB036369/ AB036371/ AB036374/ AB036376/ AB036377/ AB036378/ AB181224/ ABO45421/ ABO45441/ ABO45476/ ABO45478/ ABO45481/ ABO45483/ ABO45490/ ABO45510/ ABO45520/ ABO45521/ ABO45529/ ABO45530/ ABO45547/ ABO45549/ ABO45550/ ABO45558/ ABO45559/ AF042071/ AF054627/ AF063819/ AF063820/ AF063821/ AF076254/ AF076255/ AF076256/ AF076258/ AF076259/ AF076261/ AF076262/ AF076263/ AF076264/ AF076267/ AF133522/ AF259264/ AF292000/ AF485380/ AF485381/ D00294/ D13784/ D23690/ D23693/ DQ323750/ DQ323832/ DQ323833/ DQ323883/ HTU19949/ J02029/ J02030/ K02722/ L02534/ L03562/ L36905/ L42253/ L72212/ L76025/ L76026/ L76028/ L76029/ L76030/ L76034/ L76310/ M37299/ M69044/ M81248/ M86840/ S67443/ U12804/ U12805/ U12806/ U12807/ U19949/ U32552/ U32557/ U87264/ X88871/ X88872/ X88873/ X88876/ Y16475/ Y16477/ Y16478/ Y16479/ Y16480/ Y16481/ Y16482/ Y16483/ Y16484/ Y16487/ Z31661/ Z32527
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


85. Ng AK: Diffuse large B-cell lymphoma. Semin Radiat Oncol; 2007 Jul;17(3):169-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse large B-cell lymphoma.
  • Diffuse large B-cell lymphoma (DLBCL) is one of the most common subtypes of non-Hodgkin lymphoma.
  • It is a heterogeneous disease, and a distinctive subgroup of patients with different treatment outcome can be identified based on clinical and molecular prognostic factors.
  • Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy has been the standard systemic therapy for this disease with a cure rate of 40% to 50%, although, more recently, the addition of rituximab has been shown in phase III trials to confer a significant survival benefit in both older and younger patients.
  • To further improve on the treatment outcome of this disease, dose-dense, and/or dose-intense regimens have been developed and tested against CHOP.
  • In patients with localized DLBCL, available randomized trials suggest that radiation therapy improves local control and disease-free survival and that the addition of radiation therapy cannot replace inadequate chemotherapy.
  • [MeSH-major] Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / radiotherapy
  • [MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Humans. Neoadjuvant Therapy. Neoplasm Recurrence, Local / prevention & control. Prednisone / administration & dosage. Prednisone / therapeutic use. Radiotherapy Dosage. Rituximab. Survival Rate. Treatment Outcome. Vincristine / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17591563.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 46
  •  go-up   go-down


86. Medina-Sanson A, Chico-Ponce de León F, Cabrera-Muñoz Mde L, Gallegos-Castorena S, Caltenco-Serrano R, Barragán-Pérez E: Primary central nervous system non-Hodgkin lymphoma in childhood presenting as bilateral optic neuritis. Childs Nerv Syst; 2006 Oct;22(10):1364-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary central nervous system non-Hodgkin lymphoma in childhood presenting as bilateral optic neuritis.
  • INTRODUCTION: Primary central nervous system lymphoma is a very rare condition in pediatric patients.
  • At the time of presentation, the only positive finding was optic disk swelling, and the brain MRI scan was normal.
  • Seventeen months later, she developed a large-cell non-Hodgkin lymphoma in the brain, with no evidence of neoplasia elsewhere.
  • CONCLUSION: This case is the only non-Hodgkin lymphoma with primary central nervous system location treated in our institution in the last 10 years and represents less than 0.5% of our non-Hodgkin lymphoma series.
  • Due to its rare occurrence, not much is known about the clinical features and treatment outcome of primary central nervous system lymphoma in pediatric patients.
  • [MeSH-major] Central Nervous System Neoplasms / complications. Lymphoma, Non-Hodgkin / complications. Optic Neuritis / etiology


87. Scheckenbach K, Winterhalter S, Chaker A, Hoffmann TK, Ramp U, Wagenmann M: [MALT lymphoma of the orbit]. HNO; 2008 Feb;56(2):161-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [MALT lymphoma of the orbit].
  • [Transliterated title] MALT-Lymphom der Orbita.
  • MALT lymphomas of the orbit are rare orbital tumors; the differential diagnosis needs to exclude inflammatory pseudotumors of the orbit, but also benign lymphoproliferations, pseudolymphomas, and other orbital neoplasms.
  • After histological confirmation of the diagnosis staging is necessary, and - as long as the disease is localized exclusively in the orbit - radiation therapy should be started.
  • The clinical picture of MALT lymphoma and its differential diagnosis and treatment are discussed with reference to an actual case.
  • [MeSH-major] Lymphoma, B-Cell, Marginal Zone / diagnosis. Orbital Neoplasms / diagnosis
  • [MeSH-minor] Aged. Antigens, CD20 / analysis. Antigens, CD3 / analysis. Biopsy. Chromosome Aberrations. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. Diagnosis, Differential. Diplopia / etiology. Dose Fractionation. Endoscopy. Exophthalmos / etiology. Female. Follow-Up Studies. Humans. Ki-67 Antigen / analysis. Magnetic Resonance Imaging. Neoplasm Staging. Oculomotor Muscles / pathology. Orbit / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur Arch Otorhinolaryngol Suppl. 1993;1:227-53 [8374340.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):172-6 [12909230.001]
  • [Cites] Ann Hematol. 2005 Jan;84(1):13-8 [15309523.001]
  • [Cites] Curr Treat Options Oncol. 2003 Aug;4(4):269-79 [12943607.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):865-71 [12910532.001]
  • [Cites] Clin Cancer Res. 2004 Jan 15;10(2):476-80 [14760068.001]
  • [Cites] HNO. 2001 Jan;49(1):21-8 [11219405.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Klin Monbl Augenheilkd. 2000 Aug;217(2):133-5 [11022670.001]
  • [Cites] Curr Opin Ophthalmol. 2002 Dec;13(6):347-51 [12441835.001]
  • (PMID = 17143610.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3; 0 / Ki-67 Antigen
  •  go-up   go-down


88. Link BK, Friedberg JW: Monoclonal antibodies in lymphoma: the first decade. Semin Hematol; 2008 Apr;45(2):71-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Monoclonal antibodies in lymphoma: the first decade.
  • The past decade has seen improvements in overall survival (OS) for patients with the two most common lymphoma histologies: diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).
  • This issue will explore the impact of monoclonal antibody therapy on outcome in indolent lymphoma, and detail how this improved outcome has changed clinical practice.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2007 May 2;99(9):706-14 [17470738.001]
  • [Cites] Cancer. 2007 May 15;109(10):2077-82 [17394190.001]
  • [Cites] J Clin Oncol. 2007 May 20;25(15):1986-92 [17420513.001]
  • [Cites] Clin Adv Hematol Oncol. 2007 Oct;5(10):782-4 [17998896.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Am J Manag Care. 2003 May;9(5):393-400; quiz 401-2 [12744301.001]
  • [Cites] Blood. 2004 Nov 15;104(10):3064-71 [15284112.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5027-33 [15955905.001]
  • [Cites] J Clin Oncol. 2005 Aug 1;23(22):5019-26 [15983392.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3725-32 [16123223.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8447-52 [16230674.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1582-9 [16575009.001]
  • (PMID = 18381100.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA102216-05; United States / NCI NIH HHS / CA / K23 CA102216; United States / NCI NIH HHS / CA / CA-102216; United States / NCI NIH HHS / CA / K23 CA102216-05
  • [Publication-type] Introductory Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antibodies, Neoplasm; 0 / Antineoplastic Agents; 0 / Drugs, Investigational; 4F4X42SYQ6 / Rituximab
  • [Other-IDs] NLM/ NIHMS45948; NLM/ PMC2577815
  •  go-up   go-down


89. Mallant M, Hadithi M, Al-Toma AB, Kater M, Jacobs M, Manoliu R, Mulder C, van Waesberghe JH: Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma. World J Gastroenterol; 2007 Mar 21;13(11):1696-700
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Abdominal computed tomography in refractory coeliac disease and enteropathy associated T-cell lymphoma.
  • AIM: To evaluate computed tomography (CT) findings, useful to suggest the presence of refractory celiac disease (RCD) and enteropathy associated T cell lymphoma (EATL).
  • METHODS: Coeliac disease (CD) patients were divided into two groups.
  • Group I: uncomplicated CD (n = 14) and RCD type I (n = 10).
  • Group II: RCD type II (n = 15) and EATL (n = 7).
  • [MeSH-major] Celiac Disease / radiography. Lymphoma, T-Cell / radiography. Tomography, X-Ray Computed / methods
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Diagnosis, Differential. Female. Humans. Intestines / pathology. Intestines / radiography. Male. Mesentery / blood supply. Middle Aged. Organ Size. Radiography, Abdominal / methods. Spleen / pathology

  • Genetic Alliance. consumer health - Enteropathy-Associated T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Celiac Disease.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dig Liver Dis. 2002 Sep;34 Suppl 2:S150-3 [12408460.001]
  • [Cites] Radiology. 1999 May;211(2):389-94 [10228518.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Sep 1;18(5):487-94 [12950421.001]
  • [Cites] Abdom Imaging. 2004 Jan-Feb;29(1):15-7 [15160747.001]
  • [Cites] Br J Radiol. 1980 Jun;53(630):532-7 [7426864.001]
  • [Cites] Gut. 1983 Mar;24(3):228-30 [6826107.001]
  • [Cites] AJR Am J Roentgenol. 1985 Feb;144(2):299-302 [3871273.001]
  • [Cites] Am J Gastroenterol. 1985 Jan;80(1):27-9 [3966450.001]
  • [Cites] Radiology. 1986 Mar;158(3):605-11 [3945730.001]
  • [Cites] Gastroenterology. 1986 Jun;90(6):2008-12 [3699417.001]
  • [Cites] AJR Am J Roentgenol. 1987 Jun;148(6):1129-32 [3495136.001]
  • [Cites] Radiographics. 1989 Nov;9(6):1045-66 [2685933.001]
  • [Cites] AJR Am J Roentgenol. 1991 Jan;156(1):23-32 [1898566.001]
  • [Cites] J Clin Gastroenterol. 1993 Jun;16(4):317-9 [8331266.001]
  • [Cites] Lancet. 1994 Jan 22;343(8891):200-3 [7904667.001]
  • [Cites] J Comput Assist Tomogr. 1995 Mar-Apr;19(2):319-20 [7890865.001]
  • [Cites] Baillieres Clin Gastroenterol. 1995 Jun;9(2):351-69 [7549031.001]
  • [Cites] Histopathology. 1995 Oct;27(4):349-54 [8847065.001]
  • [Cites] Eur Radiol. 2000;10(1):119-22 [10663727.001]
  • [Cites] Scand J Gastroenterol Suppl. 2000;(232):32-7 [11232488.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1123-8 [11564968.001]
  • [Cites] Int J Colorectal Dis. 2002 May;17(3):192-8 [12049314.001]
  • [Cites] Acta Paediatr Suppl. 1996 May;412:36-8 [8783753.001]
  • [Cites] Eur Radiol. 1997;7(2):246-8 [9038125.001]
  • [Cites] Radiology. 1999 Sep;212(3):853-60 [10478257.001]
  • [Cites] Dig Liver Dis. 2005 Jun;37(6):402-6 [15893278.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Jun;19(3):413-24 [15925846.001]
  • [Cites] Gastroenterol Clin North Am. 2002 Sep;31(3):777-99 [12481731.001]
  • (PMID = 17461472.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4146948
  •  go-up   go-down


90. Martinez A, Carreras J, Campo E: The follicular lymphoma microenvironment: From tumor cell to host immunity. Curr Hematol Malig Rep; 2008 Oct;3(4):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The follicular lymphoma microenvironment: From tumor cell to host immunity.
  • Follicular lymphoma (FL) is a neoplasm derived from follicular germinal center cells.
  • Like the normal components of this lymphoid structure, FL cells interact with various immune cells, such as the follicular helper T cells, suppressor regulatory T cells, dendritic cells, and histiocytes, that define the tumor microenvironment.
  • The immune system may either promote or constrain tumor cell development, depending on the relative distribution and activation status of various cell subpopulations.
  • Some efforts have been carried out to validate those findings and provide clinical tools that may be used at the time of diagnosis.
  • [MeSH-major] Lymphoma, Follicular / immunology
  • [MeSH-minor] Cytokines / metabolism. Dendritic Cells / immunology. Forkhead Transcription Factors / metabolism. Gene Expression Regulation, Neoplastic. Germinal Center / immunology. Germinal Center / metabolism. Humans. Immunotherapy. T-Lymphocytes, Helper-Inducer / immunology. T-Lymphocytes, Regulatory / immunology

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6358-63 [16155020.001]
  • [Cites] Virchows Arch B Cell Pathol Incl Mol Pathol. 1983;44(1):85-98 [6138896.001]
  • [Cites] Haematologica. 2006 Dec;91(12):1605-12 [17145596.001]
  • [Cites] Eur J Immunol. 2007 Jan;37(1):14-6 [17183610.001]
  • [Cites] Annu Rev Immunol. 2008;26:741-66 [18173374.001]
  • [Cites] Blood. 2002 May 1;99(9):3376-82 [11964306.001]
  • [Cites] Blood. 2005 Sep 15;106(6):2169-74 [15933054.001]
  • [Cites] Blood. 2008 May 1;111(9):4764-70 [18174380.001]
  • [Cites] Blood. 2002 Jan 1;99(1):282-9 [11756183.001]
  • [Cites] Ann Oncol. 2006 Oct;17(10):1539-45 [16940035.001]
  • [Cites] Immunology. 2005 Jan;114(1):2-10 [15606789.001]
  • [Cites] Am J Clin Pathol. 1991 Jan;95(1):55-62 [1899000.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):390-8 [17200149.001]
  • [Cites] Blood. 2007 Apr 1;109(7):3076-9 [17138820.001]
  • [Cites] J Clin Invest. 2004 Dec;114(11):1640-9 [15578096.001]
  • [Cites] Cancer Lett. 2007 Oct 28;256(2):196-206 [17624663.001]
  • [Cites] J Clin Oncol. 2006 Nov 1;24(31):5052-9 [17033038.001]
  • [Cites] Leukemia. 2007 Jan;21(1):18-29 [17039231.001]
  • [Cites] N Engl J Med. 2004 Nov 18;351(21):2159-69 [15548776.001]
  • [Cites] J Immunol. 2007 Oct 15;179(8):5099-108 [17911595.001]
  • [Cites] Eur J Immunol. 2006 Nov;36(11):2832-6 [17051620.001]
  • [Cites] Nat Rev Cancer. 2008 Apr;8(4):299-308 [18354418.001]
  • [Cites] J Pathol. 2003 Nov;201(3):404-12 [14595752.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1926-30 [12571354.001]
  • [Cites] J Clin Oncol. 2005 Apr 1;23 (10 ):2215-23 [15684317.001]
  • [Cites] Blood. 2006 May 15;107(10):3925-32 [16418326.001]
  • [Cites] Genes Immun. 2006 Dec;7(8):615-24 [16971956.001]
  • [Cites] Haematologica. 2007 Aug;92 (8):1059-66 [17640856.001]
  • [Cites] Science. 2006 Sep 29;313(5795):1960-4 [17008531.001]
  • [Cites] Blood. 1997 May 15;89(10):3806-16 [9160688.001]
  • [Cites] Blood. 2006 Nov 1;108(9):2957-64 [16825494.001]
  • [Cites] J Clin Oncol. 2006 Dec 1;24(34):5350-7 [17135637.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1190-200 [18580679.001]
  • [Cites] Blood. 2005 Jan 1;105(1):301-7 [15345589.001]
  • [Cites] J Exp Med. 1992 Feb 1;175(2):371-6 [1732410.001]
  • [Cites] Oncol Rep. 2005 May;13(5):819-24 [15809744.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 [16344461.001]
  • [Cites] Nat Rev Immunol. 2008 Jan;8(1):22-33 [18097447.001]
  • [Cites] J Clin Oncol. 2008 Jan 20;26(3):440-6 [18086798.001]
  • [Cites] N Engl J Med. 1974 Apr 11;290(15):813-9 [4544736.001]
  • [Cites] Nat Rev Immunol. 2002 Mar;2(3):151-61 [11913066.001]
  • [Cites] J Clin Oncol. 2005 Sep 10;23(26):6370-8 [16155022.001]
  • [Cites] Blood. 2007 Dec 15;110(13):4455-63 [17827388.001]
  • (PMID = 20425464.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cytokines; 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  • [Number-of-references] 43
  •  go-up   go-down


91. Naresh KN, May PC, Reid AG, Marks AJ, Macdonald D, Kanfer E: T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow. Histopathology; 2010 Oct;57(4):549-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T cell lymphoblastic leukaemia/lymphoma associated with a microenvironment of thymic asteroid B cells in the bone marrow.
  • AIMS:   Asteroid B cells are a component of normal thymus.
  • It is currently unclear whether these cells are identifiable in T cell lymphoblastic leukaemia/lymphoma (T-ALL/LBL) of the thymus.
  • The aim of this study was to identify asteroid B cells both in thymic and extrathymic tissue involved by T-ALL/LBL.
  • The BMTB samples of two of eight T-ALL/LBLs and LN sample in one of them showed the presence of asteroid-shaped B cells with dendritic cytoplasmic processes.
  • These B cells also expressed CD23 and the features were akin to the unique thymic asteroid B cells.
  • Both patients had aggressive/resistant disease.
  • Cytogenetic analysis in one showed a complex translocation involving the T cell receptor beta (TCRB) gene at 7q35 and a distal region of 9q known to harbour the NOTCH1 gene.
  • CONCLUSION:   This is the first report of T-ALL/LBL documenting the presence of an asteroid B cell-rich microenvironment at bone marrow and LN sites.
  • In this small subset, T-ALL/LBL cells are possibly dependent upon asteroid B cells, and whether targeting of asteroid B cells with anti-CD20 monoclonal antibody in such cases will result in clinical benefit remains to be determined.
  • [MeSH-major] B-Lymphocytes / pathology. Bone Marrow / pathology. Lymph Nodes / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Thymus Gland / pathology
  • [MeSH-minor] Bone Marrow Cells / immunology. Bone Marrow Cells / pathology. Humans. In Situ Hybridization, Fluorescence. Male. Middle Aged

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Limited.
  • (PMID = 20875071.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


92. Joshi AD, Dickinson JD, Hegde GV, Sanger WG, Armitage JO, Bierman PJ, Bociek RG, Devetten MP, Vose JM, Joshi SS: Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion. Cancer Genet Cytogenet; 2007 Jan 15;172(2):120-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bulky lymphadenopathy with poor clinical outcome is associated with ATM downregulation in B-cell chronic lymphocytic leukemia patients irrespective of 11q23 deletion.
  • B-cell chronic lymphocytic leukemia (B-CLL) is the most common B-cell leukemia among older populations in Western countries.
  • The clinical course of B-CLL is heterogeneous: in some patients the disease course is indolent, in others it is aggressive.
  • The B-CLL subgroups with chromosome 11q23 deletion have been associated with aggressive disease course involving ATM deletion, extensive bulky lymphadenopathy (BLA), and inferior clinical outcome.
  • Moreover, gene expression analysis in B-CLL patients with and without BLA revealed differences in expression for genes involved in apoptosis, cell cycle, and cell adhesion.
  • These results indicate an association between BLA and reduced expression of ATM, suggesting a role for ATM in disease progression in B-CLL.
  • [MeSH-major] Cell Cycle Proteins / biosynthesis. Cell Cycle Proteins / genetics. Chromosome Deletion. Chromosomes, Human, Pair 11 / genetics. DNA-Binding Proteins / biosynthesis. DNA-Binding Proteins / genetics. Down-Regulation / genetics. Gene Expression Regulation, Leukemic. Leukemia, Lymphocytic, Chronic, B-Cell / genetics. Lymphatic Diseases / genetics. Protein-Serine-Threonine Kinases / biosynthesis. Protein-Serine-Threonine Kinases / genetics. Tumor Suppressor Proteins / biosynthesis. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Ataxia Telangiectasia Mutated Proteins. Cell Adhesion / genetics. Cell Cycle / genetics. Female. Humans. Male. Middle Aged. Prognosis

  • Genetic Alliance. consumer health - Chronic Lymphocytic Leukemia.
  • Genetic Alliance. consumer health - Leukemia, B-cell, chronic.
  • MedlinePlus Health Information. consumer health - Lymphatic Diseases.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17213020.001).
  • [ISSN] 0165-4608
  • [Journal-full-title] Cancer genetics and cytogenetics
  • [ISO-abbreviation] Cancer Genet. Cytogenet.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Proteins; EC 2.7.11.1 / ATM protein, human; EC 2.7.11.1 / Ataxia Telangiectasia Mutated Proteins; EC 2.7.11.1 / Protein-Serine-Threonine Kinases
  •  go-up   go-down


93. Zain J, O'Connor O: Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother; 2010 Jul;11(10):1705-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pralatrexate: basic understanding and clinical development.
  • IMPORTANCE OF THE FIELD: Pralatrexate (PDX; 10-propargyl 10-deazaaminopterin), is an exciting new chemotherapeutic agent that is approved for the treatment of relapsed and refractory peripheral T-cell lymphomas (PTCL).
  • AREAS COVERED IN THIS REVIEW: This review describes the clinical development of PDX from its synthesis to its FDA approval.
  • This is followed by a description of the preclinical data that led to early-phase clinical trials in lung cancer and lymphoma and, finally, the definitive trial that led to its approval in PTCL.
  • The review also describes how PDX is being combined with other agents in both the preclinical and clinical arenas.
  • It is active in T-cell lymphomas and non-small-cell lung cancer.
  • [MeSH-minor] Animals. Carcinoma, Non-Small-Cell Lung / drug therapy. Clinical Trials as Topic. Drug Evaluation, Preclinical. Humans. Lung Neoplasms / drug therapy. Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. AMINOPTERIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20509772.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 10-propargyl-10-deazaaminopterin; 0 / Folic Acid Antagonists; JYB41CTM2Q / Aminopterin
  • [Number-of-references] 34
  •  go-up   go-down


94. Springinsfeld G, Guillaume JC, Boeckler P, Tortel MC, Cribier B: [Two cases of subcutaneous panniculitis-like T-cell lymphoma (CD4- CD8+ CD56-)]. Ann Dermatol Venereol; 2009 Mar;136(3):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of subcutaneous panniculitis-like T-cell lymphoma (CD4- CD8+ CD56-)].
  • [Transliterated title] Lymphome T sous-cutané (CD4- CD8+ CD56-) à type de panniculite: deux cas.
  • BACKGROUND: Subcutaneous T-cell lymphoma is a rare disease and diagnosis is often difficult.
  • We report two cases of subcutaneous T-cell lymphoma simulating panniculitis and initially treated with systemic steroids.
  • Histological and immunohistochemical analysis revealed subcutaneous T-cell lymphoma of CD4- CD8+ CD56- phenotype.
  • In the context of new panniculitis lesions, histological examination showed a dense lymphocytic infiltrate involving the fat lobules.
  • Lymphocyte immunophenotyping and genotyping led to a diagnosis of subcutaneous T-cell lymphoma of CD4- CD8+ CD56- phenotype.
  • Molecular analysis showed T-cell monoclonality (alpha beta).
  • DISCUSSION: A distinction is currently made between two types of subcutaneous T-cell lymphomas and the prognosis and therapeutic consequences differ widely.
  • In our two patients, subcutaneous CD8+ T-cell lymphoma was diagnosed.
  • The clinical course was indolent in both cases.
  • Differential diagnosis with regard to lupus panniculitis can be difficult because of its slow progression.
  • In such cases of low-grade lymphomas, first-line therapy may be limited to systemic corticosteroids.
  • [MeSH-major] Antigens, CD4 / analysis. Antigens, CD56 / genetics. Antigens, CD8 / analysis. Lymphoma, T-Cell / pathology. Panniculitis / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Aged. Antigens, CD / analysis. Antigens, CD / genetics. Diagnosis, Differential. Female. Humans. Middle Aged. Phenotype

  • Genetic Alliance. consumer health - Panniculitis.
  • Genetic Alliance. consumer health - Subcutaneous panniculitis-like T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19328310.001).
  • [ISSN] 0151-9638
  • [Journal-full-title] Annales de dermatologie et de vénéréologie
  • [ISO-abbreviation] Ann Dermatol Venereol
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Antigens, CD; 0 / Antigens, CD4; 0 / Antigens, CD56; 0 / Antigens, CD8
  •  go-up   go-down


95. Ashfaq K, Yahaya I, Hyde C, Andronis L, Barton P, Bayliss S, Chen YF: Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review. Health Technol Assess; 2010 Dec;14(54):iii-iv, ix-xi, 1-141
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical effectiveness and cost-effectiveness of stem cell transplantation in the management of acute leukaemia: a systematic review.
  • Haemopoietic stem cell transplantation (SCT) has developed as an adjunct to or replacement for conventional chemotherapy with the aim of improving survival and quality of life.
  • OBJECTIVES: A systematic overview of the best available evidence on the clinical effectiveness and cost-effectiveness of SCT in the treatment of acute leukaemia.
  • DATA SOURCES: Clinical effectiveness: electronic databases, including MEDLINE, EMBASE and the Cochrane Library, were searched from inception to December 2008 to identify published systematic reviews and meta-analyses.
  • Included randomised controlled trials (RCTs) and donor versus no donor (DvND) studies were mapped to the evidence covered in existing systematic reviews and meta-analyses according to a framework of 12 decision problems (DPs): DP1 related to SCT in adults with AML in first complete remission (CR1); DP2 to adults with AML in second or subsequent remission or with refractory disease (CR2+); DP3 to children with AML in CR1; DP4 to children with AML in CR2+; DP5 to adults with ALL in CR1; DP6 to adults with ALL in CR2+; DP7 to children with ALL in CR1; DP8 to children with ALL in CR2+; DP9 to comparison of different sources of stem cells in transplantation; DP10 to different conditioning regimens; DP11 to the use of purging in autologous SCT; and DP12 to the use of T-cell depletion in allogeneic SCT.
  • RESULTS: Fifteen systematic reviews/meta-analyses met the inclusion criteria for the review of clinical effectiveness, thirteen of which were published from 2004 onwards.
  • The best available evidence for effectiveness of allogeneic SCT using stem cells from matched sibling donors came from DvND studies: there was sufficient evidence to support the use of allogeneic SCT in DP1 (except in good-risk patients), DP3 (role of risk stratification unclear) and DP5 (role of risk stratification unclear).
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / methods. Leukemia, Myeloid, Acute / surgery. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery


96. Pan JL, Xue YQ, Jiang HY, Zhu YJ, Ma L, Li TY, Wang Y, Wu YF: [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)]. Zhonghua Xue Ye Xue Za Zhi; 2005 Aug;26(8):485-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of 7 cases of acute lymphoblastic leukemia with dic(7;9) (pll;pll)].
  • OBJECTIVE: To investigate the laboratory and clinical features of 7 cases of acute lymphoblastic leukemia (ALL) with dic(7;9) (pll;pll).
  • METHODS: Cytogenetic examination of bone marrow cells was performed by direct method or short-term culture method.
  • RESULTS: Seven (0.88%) of 800 ALL patients were found to have dic(7;9) abnormality.
  • Among them, dic(7;9) was the sole abnormality in 2 cases, t(9;22), other additional aberrations besides dic(7;9) in 4 cases and dic (7;9) with other abnormalities but no t(9;22) in one case.
  • CONCLUSION: dic(7;9) was a rare, but recurrent chromosome abnormality in ALL and had some clinical and laboratory features.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16383241.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


97. Kampitak T: Polymyalgia rheumatica as the first presentation of metastatic lymphoma. Intern Med; 2010;49(15):1641-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Polymyalgia rheumatica as the first presentation of metastatic lymphoma.
  • She was given the diagnosis of polymyalgia rheumatica (PMR) due to high erythrocyte sedimentation rate.
  • She later discovered a breast lump of which histopathological tissue was consistent with a diffuse large B-cell lymphoma.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Polymyalgia Rheumatica / diagnosis
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Diagnosis, Differential. Female. HIV Infections / complications. HIV Infections / diagnosis. HIV Infections / drug therapy. Humans. Middle Aged

  • MedlinePlus Health Information. consumer health - Polymyalgia Rheumatica.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20686306.001).
  • [ISSN] 1349-7235
  • [Journal-full-title] Internal medicine (Tokyo, Japan)
  • [ISO-abbreviation] Intern. Med.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


98. Hernandez-Ilizaliturri FJ, Czuczman MS: Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park); 2009 May;23(6):546-53
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
  • The addition of rituximab to systemic chemotherapy has improved the response rates, progression-free survival, and overall survival of patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) compared to chemotherapy alone.
  • In the front-line setting, the use of rituximab is changing the biology and clinical behavior in DLBCL patients who fail to respond or relapse following chemoimmunotherapy.
  • Based on retrospective studies, it is becoming evident that the subset of patients with rituximab/chemotherapy-relapsed/refractory DLBCL represents a different clinical entity with a higher degree of chemotherapy resistance compared to DLBCL patients receiving upfront chemotherapy alone.
  • The backbone of treatment for "sensitive"patients with relapsed/refractory disease continues to be salvage chemotherapy with or without rituximab, followed by high-dose chemotherapy and autologous stem cell support.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / therapeutic use. Dose-Response Relationship, Drug. Humans. Organoplatinum Compounds / therapeutic use. Randomized Controlled Trials as Topic. Rituximab. Salvage Therapy. Stem Cell Transplantation. Transplantation, Autologous

  • Genetic Alliance. consumer health - Large B cell diffuse lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544696.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 4F4X42SYQ6 / Rituximab; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 34
  •  go-up   go-down


99. Chang ST, Lu CL, Chuang SS: CD52 expression in non-mycotic T- and NK/T-cell lymphomas. Leuk Lymphoma; 2007 Jan;48(1):117-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD52 expression in non-mycotic T- and NK/T-cell lymphomas.
  • Campath-1H or alemtuzumab, a human anti-CD52, has been shown to be effective in T-cell malignancies; however, there is very limited information on CD52 expression in T-cell lymphoma (TCL).
  • Fourteen cases of angioimmunoblastic T-cell lymphoma (AITL) were excluded as there were no reliable criteria to differentiate whether the CD52-positive cells were neoplastic T-cells, which are usually small-sized, or the usually abundant, small-to-large residual/reactive B-cells in this lymphoma sub-type.
  • In the remaining 83 tumors, CD52 was expressed in 29 (35%) tumors including 8/17 (47%) NK/T-cell lymphomas, 14/35 (40%) unspecified peripheral TCLs and 4/18 (22%) anaplastic large cell lymphomas.
  • The authors recommend performing CD52 immunostaining for future clinical trials of alemtuzumab on TCL patients and to correlate the staining results with treatment outcome.
  • [MeSH-major] Antigens, CD / metabolism. Antigens, Neoplasm / metabolism. Glycoproteins / metabolism. Lymphoma, T-Cell / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Killer Cells, Natural / metabolism. Killer Cells, Natural / pathology. Male. Middle Aged. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17325855.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins
  •  go-up   go-down


100. Park SI, Press OW: Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies. Curr Opin Hematol; 2007 Nov;14(6):632-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radioimmunotherapy for treatment of B-cell lymphomas and other hematologic malignancies.
  • This review will present the latest information on radioimmunotherapy for treatment of hematologic malignancies in various clinical settings and assess its long-term safety profile.
  • RECENT FINDINGS: Recent data suggest that radioimmunotherapy with 131I-tositumomab or 90Y-ibritumomab tiuxetan not only induces high response rates but also results in durable remissions in patients with relapsed or refractory indolent non-Hodgkin's lymphomas.
  • Even more notable response rates have been observed when radioimmunotherapy is used as front-line treatment in patients with indolent non-Hodgkin's lymphomas.
  • The use of radioimmunotherapy has been evaluated in the treatment of aggressive lymphomas with promising results, but it remains investigational.
  • Standard doses of radioimmunotherapy given as a conditioning regimen for hematopoietic stem-cell transplant or myeloablative doses of radioimmunotherapy given in conjunction with stem-cell support have yielded encouraging outcomes with durable remissions and a low incidence of treatment-related mortality.
  • SUMMARY: The safety and efficacy of radioimmunotherapy has been demonstrated for patients with B-cell lymphomas and other hematologic malignancies in various clinical settings.
  • A number of randomized phase III clinical trials are currently underway to further define radioimmunotherapy's role in the treatment of lymphomas.
  • [MeSH-major] Lymphoma, B-Cell / therapy. Radioimmunotherapy / methods
  • [MeSH-minor] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Humans. Lymphoma / immunology. Lymphoma / therapy. Radiopharmaceuticals / therapeutic use

  • Genetic Alliance. consumer health - B-Cell Lymphomas.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17898567.001).
  • [ISSN] 1065-6251
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA44991
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / Radiopharmaceuticals; 0 / ibritumomab tiuxetan; 0 / iodine-131 anti-B1 antibody
  • [Number-of-references] 45
  •  go-up   go-down






Advertisement